<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections - Shiu, JR - 2013 | Cochrane Library</title> <meta content="Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections - Shiu, JR - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008481.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections - Shiu, JR - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008481.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008481.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections" name="citation_title"/> <meta content="Jennifer R Shiu" name="citation_author"/> <meta content="Alberta Health Services" name="citation_author_institution"/> <meta content="Erica Wang" name="citation_author"/> <meta content="Interior Health Authority" name="citation_author_institution"/> <meta content="Aaron M Tejani" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Aaron.Tejani@fraserhealth.ca" name="citation_author_email"/> <meta content="Michael Wasdell" name="citation_author"/> <meta content="Bridgepoint Collaboratory for Research and Innovation Bridgepoint Health" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD008481.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/03/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008481.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008481.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008481.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Anti‐Bacterial Agents [*administration &amp; dosage, pharmacokinetics]; Bacterial Infections [*drug therapy, metabolism, mortality]; Infusions, Intravenous [methods]; Randomized Controlled Trials as Topic; Recurrence" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008481.pub2&amp;doi=10.1002/14651858.CD008481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Nio3SV1W";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008481\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008481\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008481.pub2",title:"Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections",firstPublishedDate:"Mar 28, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Injuries Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008481.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008481.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008481.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008481.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008481.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008481.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008481.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008481.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008481.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008481.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10984 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008481.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-sec-0075"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-sec-0057"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-sec-0069"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/appendices#CD008481-sec-0080"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/table_n/CD008481StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/table_n/CD008481StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/information#CD008481-cr-0002">Jennifer R Shiu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/information#CD008481-cr-0003">Erica Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/information#CD008481-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Aaron M Tejani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008481.pub2/information#CD008481-cr-0005">Michael Wasdell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/information/en#CD008481-sec-0084">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 March 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008481.pub2">https://doi.org/10.1002/14651858.CD008481.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008481-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008481-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008481-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008481-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008481-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008481-abs-0001" lang="en"> <section id="CD008481-sec-0001"> <h3 class="title" id="CD008481-sec-0001">Background</h3> <p>Intravenous broad–spectrum antibiotics are indicated for the treatment of severe infections. However, the emergence of infections caused by multiple‐drug resistant organisms in conjunction with a lack of novel antibiotics has prompted the investigation of alternative dosing strategies to improve clinical efficacy and tolerability. To optimise pharmacokinetic and pharmacodynamic antibiotic parameters, continuous antibiotic infusions have been compared with traditional intermittent antibiotic infusions. </p> </section> <section id="CD008481-sec-0002"> <h3 class="title" id="CD008481-sec-0002">Objectives</h3> <p>To compare the clinical efficacy and safety of continuous intravenous administration of concentration–dependent and time–dependent antibiotics with traditional intermittent intravenous administration in adults with severe acute bacterial infections.  </p> </section> <section id="CD008481-sec-0003"> <h3 class="title" id="CD008481-sec-0003">Search methods</h3> <p>The following electronic databases were searched in September 2012: The Cochrane Injuries Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), <i>The Cochrane Library</i>, MEDLINE (OvidSP), EMBASE (OvidSP), CINAHL, ISI Web of Science: Science Citation Index Expanded (SCI‐EXPANDED), and ISI Web of Science: Conference Proceedings Citation Index‐Science (CPCI‐S). The reference lists of all relevant materials, the Internet, and the trials registry <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> for completed and ongoing trials were also searched. </p> </section> <section id="CD008481-sec-0004"> <h3 class="title" id="CD008481-sec-0004">Selection criteria</h3> <p>Randomised controlled trials in adults with a bacterial infection requiring intravenous antibiotic therapy comparing continuous versus intermittent infusions of antibiotics were included. Both time–dependent and concentration–dependent antibiotics were considered. </p> </section> <section id="CD008481-sec-0005"> <h3 class="title" id="CD008481-sec-0005">Data collection and analysis</h3> <p>Three independent authors performed data extraction for the included studies. All data were cross–checked and disagreements resolved by consensus. An intention‐to‐treat analysis was conducted using a random–effects model. </p> </section> <section id="CD008481-sec-0006"> <h3 class="title" id="CD008481-sec-0006">Main results</h3> <p>Twenty–nine studies met inclusion criteria with a combined total of more than 1600 participants. Most included studies were judged to be at unclear or high risk of bias with regard to randomisation sequence generation, allocation concealment, blinding, management of incomplete outcome data, selective outcome reporting, and other potential threats to validity. No studies were judged to be at low risk of bias for all methodological quality items assessed. No differences in all–cause mortality (n = 1241, risk ratio (RR) 0.89, 95% confidence interval (CI) 0.67 to 1.20, P = 0.45), infection recurrence (n = 398, RR 1.22, 95% CI 0.35 to 4.19, P = 0.76), clinical cure (n = 975, RR 1.00, 95% CI 0.93 to 1.08, P = 0.98), and super‐infection post–therapy (n = 813, RR 1.08, 95% CI 0.60 to 1.94, P = 0.79) were reported, nor were any differences observed in safety outcomes, including adverse events (n = 575, RR 1.02, 95% CI 0.94 to 1.12, P = 0.63), serious adverse events (n = 871, RR 1.36, 95% CI 0.80 to 2.30, P = 0.26), and withdrawals due to adverse events (n = 871, RR 2.03, 95% CI 0.52 to 7.95, P = 0.31). A difference was observed in subgroup analyses of clinical cure in septic versus non‐septic participants, in which intermittent antibiotic infusions were favoured for clinical cure in septic participants. However, this effect was not consistent between random‐effects and fixed‐effect analyses. No differences were noted in the sensitivity analyses conducted. </p> </section> <section id="CD008481-sec-0007"> <h3 class="title" id="CD008481-sec-0007">Authors' conclusions</h3> <p>No differences in mortality, infection recurrence, clinical cure, super‐infection post–therapy, and safety outcomes were reported when continuous infusions of intravenous antibiotics were compared with traditional intermittent infusions of antibiotics. However, the wide confidence intervals suggest that beneficial or harmful effects cannot be ruled out for all outcomes. Therefore, the current evidence is insufficient to recommend the widespread adoption of continuous infusion antibiotics in the place of intermittent infusions of antibiotics. Additinal large prospective randomised trials, with consistent and complete reporting of clinical outcome measures, conducted with concurrent pharmacokinetic and pharmacodynamic studies in special populations, are required to determine whether adoption of continuous antibiotic infusions is warranted in specific circumstances. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008481-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008481-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008481-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008481-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008481-abs-0004">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008481-abs-0003" lang="en"> <h3>Alternative dosing strategies for intravenous antibiotics to treat severe infections</h3> <p>Intravenous (through the vein) antibiotics are used to treat severe bacterial infections. Currently, the most common way to administer intravenous antibiotics is by intermittent infusion, whereby an antibiotic is infused into a patient over 30 minutes to 1 hour multiple times per day during the course of treatment. To optimise the efficacy and potentially the safety of these antibiotics, alternative dosing strategies have been studied. One proposed strategy is to administer intravenous antibiotics by continuous or extended infusions over 3 to 24 hours.  </p> <p>Twenty–nine randomised trials comprising more than 1600 participants were reviewed to study the effects of continuous infusion antibiotics versus intermittent infusion antibiotics. When mortality, infection recurrence, clinical cure, super‐infection after treatment, and safety concerns were considered, no differences between the two dosing strategies were noted. </p> <p>The authors conclude that because continuous antibiotic infusions provide no benefit over standard intermittent infusions, they cannot recommend continuous antibiotic infusions for widespread use. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008481-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008481-sec-0075"></div> <h3 class="title" id="CD008481-sec-0076">Implications for practice</h3> <section id="CD008481-sec-0076"> <p>No differences in mortality, infection recurrence, clinical cure, and super‐infection post–therapy were found when continuous infusions of intravenous antibiotics were compared with traditional intermittent antibiotic infusions. However, the wide confidence intervals suggest that beneficial or harmful effects cannot be ruled out for all outcomes. Although no evidence of statistical heterogeneity was found, some clinically meaningful heterogeneity between studies is likely and should be considered. Also, no differences in safety outcomes between the two interventions were apparent. Because several trials did not report data for clinically important outcomes, and because confidence intervals for effect estimates were wide, it is possible that the analyses in this review are underpowered because of lack of data. Therefore, the current available evidence is insufficient to recommend the widespread adoption of continuous infusion antibiotics in the place of standard intermittent antibiotic infusions. </p> </section> <h3 class="title" id="CD008481-sec-0077">Implications for research</h3> <section id="CD008481-sec-0077"> <p>Large, prospective randomised trials looking at additional outcomes, such as length of hospital stay, and reporting on all outcomes of interest as outlined in this review, would add to the findings of this review. It would also be helpful if these large trials were conducted with concurrent pharmacokinetic and pharmacodynamic studies. Trials investigating the effects of continuous infusion antibiotics in critically ill participants should be considered, because this population is theoretically more likely to benefit from this alternate dosing strategy based on subgroup data from previous retrospective studies. It is also not clear whether there would be additional therapeutic efficacy if continuous antibiotic infusions were used to treat more resistant organisms. Additional pharmacoeconomic studies are required to confirm whether there are other reasons to support the use of continuous infusion antibiotics. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008481-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008481-sec-0022"></div> <div class="table" id="CD008481-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Continuous versus Intermittent Antibiotic Infusions for Treatment of Severe Bacterial Infections</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Continuous versus Intermittent Antibiotic Infusions for Treatment of Severe Bacterial Infections</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patients:</b> Adults with Severe Bacterial Infections<br/> <b>Setting:</b> Hospital<br/> <b>Intervention:</b> Continuous Antibiotic Infusions<br/> <b>Comparison:</b> Intermittent Antibiotic Infusions </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intermittent antibiotic Infusions</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Continuous antibiotic Infusions</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>131 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> <br/> (88 to 157) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/> (0.67 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1241<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infection recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> <br/> (7 to 81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> <br/> (0.35 to 4.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical cure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>584 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>608 per 1000</b> <br/> (555 to 660) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/> (0.95 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>975<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Super‐infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> <br/> (29 to 95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.60 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>813<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b> <br/> (38 to 110) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> <br/> (0.80 to 2.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>871<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> <br/> (4 to 54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.03</b> <br/> (0.52 to 7.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>871<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>441 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>450 per 1000</b> <br/> (415 to 494) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/> (0.94 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>575<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008481-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008481-sec-0023"></div> <section id="CD008481-sec-0024"> <h3 class="title" id="CD008481-sec-0024">Description of the condition</h3> <p>Intravenous broad–spectrum antibiotics are indicated for the treatment of severe community–acquired or healthcare–associated infection. However, the emergence of multiple–drug resistant infections caused by organisms such as <i>Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Enterococcus faecium, Enterococcus faecalis,</i> and Enterobacteriaceae is growing worldwide (<a href="./references#CD008481-bbs2-0094" title="RosenthalVD , BijieH , MakiDG , MehtaY , ApisarnthanarakA , MedeirosEA , LeblebiciogluH , FisherD , Alvarez‐MorenoC , KhaderIA , MartinezM , CuellarLE , Navoa‐NgJA , AbouqalR , GarcellHG , MitrevZ , GarciaMCP , HamdiA , DuenasL , CancelE , GurskisV , RasslanO , AhmedA , KanjSS , UgaldeOC , MappT , RakaL , MengCY , ThuLA , GhazalS , GikasA , NarvaezLP , MejiaN , HadjievaN , ElanbyaMOG , SirittMEG , JayatillekeK , INICCmembers . International nosocomial infection control consortium (INICC) report, data summary of 36 countries, for 2004‐2009. American Journal of Infection Control2012;40(5):396‐407. ">Rosenthal 2012</a>; <a href="./references#CD008481-bbs2-0074" title="GhafourianS , SekawiZ , SadeghifardN , MohebiR , NeelaVK , MalekiA , HematianA , RahbarM , RaftariM , RanjbarR . The prevalence of ESBLs producing Klebsiella pneumoniae isolates in some major hospitals, Iran. The Open Microbiology Journal2011;5:91‐5. ">Ghafourian 2011</a>; <a href="./references#CD008481-bbs2-0086" title="MeyerE , ZieglerR , MattnerF , SchwabF , GastmeierP , MartinM . Increase of patients co‐colonised or co‐infected with methicillin‐resistant Staphylococcus aureus, vancomycin‐resistant Enterococcus faecium or extended‐spectrum B‐lactamase‐producing Enterobacteriaceae. Infection2011;39(6):501‐6. ">Meyer 2011</a>; <a href="./references#CD008481-bbs2-0088" title="NeidellMJ , CohenB , FuruyaY , HillJ , JeonCY , GliedS , LarsonEL . Costs of healthcare‐ and community‐associated infections with antimicrobial‐resistance versus susceptible organisms. Clinical Infectious Diseases2012;Jun 14:(epub ahead of print). ">Neidell 2012</a>). Such antimicrobial–resistant infections have been associated with poor outcomes, such as increases in length of hospital stay, healthcare costs, and mortality (<a href="./references#CD008481-bbs2-0095" title="SunenshineRH , WrightMO , MaragakisLL , HarrisAD , SongX , HebdenJ , CosgroveSE , AndersonA , CarnellJ , JerniganDB , KleinbaumDG , PeriTM , StandifordHC , SrinivasanA . Multidrug‐resistant Acinetobacter infection mortality rate and length of hospitalization. Emerging Infectious Diseases2007;13(1):97‐103. ">Sunenshine 2007</a>; <a href="./references#CD008481-bbs2-0088" title="NeidellMJ , CohenB , FuruyaY , HillJ , JeonCY , GliedS , LarsonEL . Costs of healthcare‐ and community‐associated infections with antimicrobial‐resistance versus susceptible organisms. Clinical Infectious Diseases2012;Jun 14:(epub ahead of print). ">Neidell 2012</a>). Despite this growing problem, few novel antibiotics have been developed in recent years; therefore, alternative dosing strategies have been investigated to improve clinical efficacy while ensuring tolerability. To optimise the pharmacokinetic and pharmacodynamic properties of antibiotics, dosing strategies such as continuous or extended intravenous antibiotic infusions have been compared with traditional intermittent intravenous antibiotic dosing. </p> </section> <section id="CD008481-sec-0025"> <h3 class="title" id="CD008481-sec-0025">Description of the intervention</h3> <p>Antibiotics are divided into categories on the basis of the pharmacokinetic and pharmacodynamic parameters associated with antibacterial efficacy. Although these bacterial kill characteristics have been determined most often from in vitro studies, this information remains important in optimising antibiotic clinical efficacy. For example, aminoglycosides, fluoroquinolones, and metronidazole are classified as concentration–dependent antibiotics, for which efficacy is determined by peak plasma drug concentration over minimum inhibitory concentration (Cmax/MIC) (<a href="./references#CD008481-bbs2-0091" title="RobertsJA , LipmanJ . Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clinical Pharmacokinetics2006;45(8):755‐73. ">Roberts 2006</a>; <a href="./references#CD008481-bbs2-0071" title="CraigWA . Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases1998;26(1):1‐10. ">Craig 1998</a>; <a href="./references#CD008481-bbs2-0087" title="MooreRD , LietmanPS , SmithCR . Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases1987;155(1):93‐9. ">Moore 1987</a>). Conversely, beta–lactams, carbapenems, clindamycin, linezolid, and clarithromycin are time–dependent or concentration–independent antibiotics for which the time the drug serum concentration remains above the minimum inhibitory concentration (T &gt; MIC) is the best predictor of efficacy (<a href="./references#CD008481-bbs2-0091" title="RobertsJA , LipmanJ . Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clinical Pharmacokinetics2006;45(8):755‐73. ">Roberts 2006</a>; <a href="./references#CD008481-bbs2-0085" title="McKinnonPS , PaladinoJA , SchentagJJ . Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T&gt;MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. International Journal of Antimicrobial Agents2008;31(4):345‐51. ">McKinnon 2008</a>; <a href="./references#CD008481-bbs2-0071" title="CraigWA . Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases1998;26(1):1‐10. ">Craig 1998</a>; <a href="./references#CD008481-bbs2-0097" title="vanZantenAR . The jury is still out on continuous infusion of B‐lactam antibiotics in intensive care patients. Critical Care Medicine2009;37(6):2137‐8. ">van Zanten 2009</a>). Although it is commonly accepted that antibiotics are divided into two main classifications, some antimicrobials exhibit more complex bacterial kill characteristics. Fluoroquinolones, azithromycin, glycopeptides, and tetracyclines are concentration–dependent antibiotics with time dependence, for which efficacy is best predicted by the area under the serum concentration–time curve during 24 hours over the minimum inhibitory concentration (AUC<sub>24</sub>/MIC) (<a href="./references#CD008481-bbs2-0091" title="RobertsJA , LipmanJ . Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clinical Pharmacokinetics2006;45(8):755‐73. ">Roberts 2006</a>; <a href="./references#CD008481-bbs2-0071" title="CraigWA . Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases1998;26(1):1‐10. ">Craig 1998</a>). </p> <p>Studies evaluating the efficacy of continuous or extended antibiotic infusions generally involve time–dependent antibiotics (<a href="./references#CD008481-bbs2-0004" title="BuckC , BertramN , AckermannT , SauerbruchT , DerendorfH , PaarWD . Pharmacokinetics of piperacillin‐tazobactam: intermittent dosing versus continuous infusion. International Journal of Antimicrobial Agents2005;25(1):62‐7. ">Buck 2005</a>; <a href="./references#CD008481-bbs2-0092" title="RobertsJA , LipmanJ , BlotS , RelloJ . Better outcomes through continuous infusion of time‐dependent antibiotics to critically ill patients?. Current Opinion in Critical Care2008;14(4):390‐6. ">Roberts 2008</a>; <a href="./references#CD008481-bbs2-0093" title="RobertsJA , WebbS , PatersonD , HoKM , LipmanJ . A systematic review on clinical benefits of continuous administration of B‐lactam antibiotics. Critical Care Medicine2009;37(6):2071‐8. ">Roberts 2009a</a>). Several time–dependent antibiotics are known to have a short half‐life; therefore, concern has arisen that the drug serum concentration will drop below the minimum inhibitory concentration (MIC) before the next scheduled intermittent infusion (<a href="./references#CD008481-bbs2-0082" title="LipmanJ , WallisSC , RickardCM , FraenkelD . Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Medicine2001;27(2):363‐70. ">Lipman 2001</a>). To optimise antibiotic kill characteristics, extended (&gt; 3‐hour intermittent infusions) or continuous (24‐hour fixed–rate infusions) administration is thought to prolong T &gt; MIC and to improve clinical efficacy (<a href="./references#CD008481-bbs2-0096" title="TammaPD , PutchaN , SuhYD , VanArendonkKJ , RinkeML . Does prolonged B‐lactam infusions improve clinical outcomes compared to intermittent infusions? A meta‐analysis and systematic review of randomized, controlled trials. BMC Infectious Diseases2011;11:181. ">Tamma 2011</a>; <a href="./references#CD008481-bbs2-0083" title="LodiseTP , LomaestroBM , DrusanoGL , Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on B‐lactam antibiotics. Pharmacotherapy2006;26(9):1320‐32. ">Lodise 2006</a>). Although T &gt; MIC targets vary between antibiotic classes (20% to 40% carbapenems, 50^ to 60% penicillins, 60% to 70% cephalosporins, 50% to 60% monobactams) (<a href="./references#CD008481-bbs2-0071" title="CraigWA . Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases1998;26(1):1‐10. ">Craig 1998</a>; <a href="./references#CD008481-bbs2-0072" title='DrusanoGL . Antimicrobial pharmacodynamics: critical interactions of "bug and drug". Nature Reviews Microbiology2004;2(4):289‐300. '>Drusano 2004</a>), improved clinical cure rates and bacteriologic eradication were observed in critically ill participants when T &gt; MIC was maintained at 100% (<a href="./references#CD008481-bbs2-0085" title="McKinnonPS , PaladinoJA , SchentagJJ . Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T&gt;MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. International Journal of Antimicrobial Agents2008;31(4):345‐51. ">McKinnon 2008</a>). It has also been suggested in comparison with intermittent infusions of vancomycin and beta–lactams, continuous infusions may reduce time to achieve therapeutic drug serum concentrations (<a href="./references#CD008481-bbs2-0092" title="RobertsJA , LipmanJ , BlotS , RelloJ . Better outcomes through continuous infusion of time‐dependent antibiotics to critically ill patients?. Current Opinion in Critical Care2008;14(4):390‐6. ">Roberts 2008</a>). In contrast, for concentration–dependent antibiotics that exhibit post–antibiotic effects, it is not known whether extended or continuous infusions would be of additional benefit because large, infrequent infusions would maximize Cmax/MIC, resulting in peak efficacy. However, for select concentration‐dependent antibiotics in which efficacy is also characterized by AUC<sub>24</sub>/MIC (e.g. fluoroquinolones), extended or continuous infusions may result in favourable clinical outcomes. </p> </section> <section id="CD008481-sec-0026"> <h3 class="title" id="CD008481-sec-0026">Why it is important to do this review</h3> <p>Previous reviews have suggested that continuous or extended infusion of time–dependent antibiotics results in more favourable pharmacodynamic outcomes. A systematic review of 17 randomised clinical trials performed by Kasiakou et al compared the pharmacokinetic and pharmacodynamic parameters of intermittent and continuous infusions of time–dependent antibiotics in hospitalised adults and in healthy volunteers (<a href="./references#CD008481-bbs2-0080" title="KasiakouSK , LawrenceKR , ChoulisN , FalagasME . Continuous versus intermittent intravenous administration of antibacterials with time‐ dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs2005;65(17):2499‐511. ">Kasiakou 2005a</a>). It was found that the mean Cmax of the intermittent infusion group was 5.5 times greater than the steady–state serum concentration (Css) of the continuous infusion group (range 1.9 to 11.2). Additionally, the Css of the continuous infusion group was 5.8 times higher than the trough serum concentration (Cmin) of the intermittent infusion group (range 1.2 to 15.6). Investigators also observed that the T &gt; MIC was longer in the continuous infusion group in three of the six studies included. </p> <p>Although it is of theoretical advantage to administer time–dependent antibiotics by continuous or extended infusion, several systematic reviews investigating this issue have not confirmed these proposed clinical benefits. A meta–analysis of nine randomised controlled trials (RCTs) performed by Kasiakou et al to compare continuous versus intermittent administration of beta–lactams, aminoglycosides, and vancomycin showed no difference in clinical failure (odds ratio (OR) 0.73, 95% CI 0.53 to 1.01) or mortality (OR 0.89, 95% CI 0.48 to 1.64) (<a href="./references#CD008481-bbs2-0081" title="KasiakouSK , SermaidesGJ , MichalopoulosA , SoteriadesES , FalagasME . Continuous versus intermittent intravenous administration of antibiotics: a meta‐analysis of randomised controlled trials. Lancet Infectious Diseases2005;5(9):581‐9. ">Kasiakou 2005b</a>). However, a subgroup analysis of those RCTs that used the same daily antibiotic dose in both intervention groups showed reduced clinical failure in the continuous infusion arm (OR 0.70, 95% CI 0.50 to 0.98) (<a href="./references#CD008481-bbs2-0081" title="KasiakouSK , SermaidesGJ , MichalopoulosA , SoteriadesES , FalagasME . Continuous versus intermittent intravenous administration of antibiotics: a meta‐analysis of randomised controlled trials. Lancet Infectious Diseases2005;5(9):581‐9. ">Kasiakou 2005b</a>). A systematic review of 14 RCTs conducted by Tamma et al in hospitalised patients showed that prolonged beta–lactam infusions rather than intermittent infusions did not affect mortality (n = 982, RR 0.92, 95% CI 0.61 to 1.37) or clinical cure (n = 1380, RR 1.00, 95% CI 0.94 to 1.06) (<a href="./references#CD008481-bbs2-0096" title="TammaPD , PutchaN , SuhYD , VanArendonkKJ , RinkeML . Does prolonged B‐lactam infusions improve clinical outcomes compared to intermittent infusions? A meta‐analysis and systematic review of randomized, controlled trials. BMC Infectious Diseases2011;11:181. ">Tamma 2011</a>). Another systematic review of 14 RCTs including 846 hospitalised patients from 9 countries also showed that continuous or extended infusion beta–lactam infusions versus bolus dosing led to no improvement in clinical cure (n = 745, OR 1.04, 95% CI 0.74 to 1.46, P = 0.83) or mortality (n = 541, OR 1.00, 95% CI 0.48 to 2.06, P = 1.00) (<a href="./references#CD008481-bbs2-0093" title="RobertsJA , WebbS , PatersonD , HoKM , LipmanJ . A systematic review on clinical benefits of continuous administration of B‐lactam antibiotics. Critical Care Medicine2009;37(6):2071‐8. ">Roberts 2009a</a>). These systematic reviews were generally well conducted; however, they were limited by small sample sizes, clinical heterogeneity in participants and infections studied, and study designs that were not blind. </p> <p>Investigators reported some improvement in pharmacodynamic outcomes with weak evidence supporting clinical benefits of continuous or extended infusion antibiotics. Therefore, the purpose of this review will be to determine whether any advantage is derived from using this alternative dosing strategy rather than conventional dosing strategies in patients with severe infection. In addition to evaluating clinical and safety outcomes of continuous versus intermittent dosing of time–dependent antibiotics, this review will be extended to include concentration–dependent antibiotics. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008481-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008481-sec-0027"></div> <p>To compare the clinical efficacy and safety of continuous intravenous administration of concentration‐dependent and time‐dependent antibiotics with traditional intermittent intravenous administration in patients with severe acute bacterial infection. Continuous intravenous infusions included extended and continuous infusions. Severe acute infection was defined as any infection requiring intravenous antibiotics. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008481-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008481-sec-0028"></div> <section id="CD008481-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008481-sec-0030"> <h4 class="title">Types of studies</h4> <p>Open‐label or blinded parallel‐group RCTs comparing continuous versus intermittent intravenous infusions of the same antibiotic were included. Cross‐over studies were excluded. </p> </section> <section id="CD008481-sec-0031"> <h4 class="title">Types of participants</h4> <p>Study participants were male or non‐pregnant female adults (18 years or older) with a bacterial infection requiring intravenous antibiotic therapy. Investigators considered different infections in this review, and no restrictions were placed on the anatomical site of infection, participant baseline risk, or co‐morbid conditions. </p> </section> <section id="CD008481-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Included studies compared continuous versus intermittent infusions of the same intravenous antibiotic. Both time‐dependent and concentration‐dependent antibiotics were included. </p> </section> <section id="CD008481-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD008481-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008481-list-0001"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Infection recurrence within 14 days of resolution of primary infection.</p> </li> </ul> </p> </section> <section id="CD008481-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008481-list-0002"> <li> <p>Clinical cure (any pre‐defined criteria specific to the infection being studied that address signs and symptoms of infection, such as fever, leukocyte counts, bacterial culture results, vital signs and visual signs or symptoms of infection, such as sputum production or inflammation, redness, or size of skin lesion). </p> </li> </ul> <ul id="CD008481-list-0003"> <li> <p>Secondary/super‐infections post‐therapy (new infection with different organisms from those observed in the primary infection). </p> </li> </ul> <ul id="CD008481-list-0004"> <li> <p>Safety:</p> <ul id="CD008481-list-0005"> <li> <p>Number of participants who experienced at least one serious adverse event (results in death, is life threatening, places the participant at immediate risk of death, requires or prolongs hospitalisation, causes permanent/significant disability or incapacity, or is another condition that investigators judge to represent significant hazards). </p> </li> <li> <p>Number of participants who withdrew as the result of adverse events.</p> </li> <li> <p>Number of participants with at least one adverse event.</p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD008481-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <p>The searches were not restricted by date, language, or publication status.</p> <section id="CD008481-sec-0037"> <h4 class="title">Electronic searches</h4> <p>The following electronic databases were searched;</p> <p> <ul id="CD008481-list-0006"> <li> <p>Cochrane Injuries Group Specialised Register (13 September 2012).</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL)<i>(The Cochrane Library)</i> 2012<i>,</i> Issue 8 of 12. </p> </li> <li> <p>MEDLINE (OvidSP) 1946 to September Week 1 2012.</p> </li> <li> <p>EMBASE (OvidSP) 1980 to 2012 Week 37.</p> </li> <li> <p>CINAHL (EBSCO) (1982 to September 2012).</p> </li> <li> <p>ISI Web of Science: Science Citation Index Expanded (SCI‐EXPANDED) (1970 to 13 September 2012). </p> </li> <li> <p>ISI Web of Science: Conference Proceedings Citation Index‐Science (CPCI‐S) (1990 to 13 September 2012). </p> </li> </ul> </p> <p>Searches were based on the MEDLINE search strategy reported in the protocol, and amendments were made, when necessary, to adapt it for the other databases. All search strategies are reported in full in <a href="./appendices#CD008481-sec-0081">Appendix 1</a>. </p> </section> <section id="CD008481-sec-0038"> <h4 class="title">Searching other resources</h4> <p>A manual search of reference lists of all relevant material was performed to identify additional potentially eligible studies. The Internet was searched using the Google search engine (<a href="http://www.google.com" target="_blank">www.google.com</a>), with selected terms from the MEDLINE strategy, to identify any further unpublished or grey literature. An online clinical trials register (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) was searched for completed and ongoing trials, and authors were contacted for information about ongoing or recently completed trials. </p> </section> </section> <section id="CD008481-sec-0039"> <h3 class="title" id="CD008481-sec-0039">Data collection and analysis</h3> <p>The Injuries Group Trials Search Co‐ordinator conducted the search using the methods described and collated the results before sending them to the authors. The review was conducted according to the previously published protocol (<a href="./references#CD008481-bbs2-0099" title="YuIS , TejaniAM , WasdellM . Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections (Protocol). Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD008481] ">Yu 2010</a>). </p> <section id="CD008481-sec-0040"> <h4 class="title">Selection of studies</h4> <p>Four independent authors (JS, EW, AT, MW) screened the titles and abstracts of the search results. Studies not meeting the pre‐defined inclusion criteria were excluded. Reasons for excluding studies that seemed to meet the inclusion criteria, but then were subsequently excluded, were documented. Studies that met the inclusion criteria were further examined. The full text of all studies that were potentially relevant was retrieved and, where necessary, was translated into English. Studies with more than one publication were examined closely to ensure that each study was counted only once, and that multiple references were included by study. </p> </section> <section id="CD008481-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>Three independent authors (JS, EW, AT) used a pre‐formed standardised data extraction sheet to record study characteristics and outcomes considered for this review. All data were cross‐checked, and differences were resolved with further examination until a consensus was reached. The data extracted from each study included the following: </p> <p> <ul id="CD008481-list-0007"> <li> <p>Participant characteristics (e.g. gender, age, ethnicity, co‐morbid conditions).</p> </li> <li> <p>Methods (e.g. random allocation procedures; allocation concealment; blinding of participants, healthcare providers, and outcome assessors). </p> </li> <li> <p>Losses to follow‐up, how they were handled, and follow‐up duration.</p> </li> <li> <p>Interventions (including antibiotic used, dose, and duration).</p> </li> <li> <p>Outcome measures as listed previously.</p> </li> </ul> </p> <p>All data were collected, regardless of compliance or completion of follow‐up, to allow for an intention‐to‐treat analysis. </p> </section> <section id="CD008481-sec-0042"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three independent authors (JS, EW, AT) assessed the methodological quality of each study using the following parameters as an evaluation tool and transcribed information from each included study into the 'Risk of bias' tables. Criteria for assessing risk of bias included evaluating the sequence generation, allocation concealment, blinding, management of incomplete data, selective outcome reporting, and other potential threats to the validity of the studies (<a href="./references#CD008481-bbs2-0078" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org. ">Higgins 2009</a>). </p> <section id="CD008481-sec-0043"> <h5 class="title">Sequence generation</h5> <p>Was sequence generation adequate?</p> <p> <ul id="CD008481-list-0008"> <li> <p>Low risk of bias: A random component of sequence generation is described (e.g. computer‐generated random sequence, random number table). </p> </li> <li> <p>High risk of bias: A non‐random component of sequence generation is described (e.g. allocation by clinician's judgement, allocation by participant's preference, sequence generated by admission date). </p> </li> <li> <p>Unclear: insufficient information to conclude 'low risk of bias' or 'high risk of bias.' </p> </li> </ul> </p> </section> <section id="CD008481-sec-0044"> <h5 class="title">Allocation concealment</h5> <p>Was allocation concealment adequate?</p> <p> <ul id="CD008481-list-0009"> <li> <p>Low risk of bias: Participants and investigators enrolling participants could not predict assignment (e.g. sequentially numbered opaque sealed envelopes, telephone randomisation). </p> </li> <li> <p>High risk of bias: Participants and investigators enrolling participants could predict assignment (e.g. unsealed envelopes, alternation). </p> </li> <li> <p>Unclear: Information is insufficient to allow conclusion of 'low risk of bias' or 'high risk of bias.' </p> </li> </ul> </p> </section> <section id="CD008481-sec-0045"> <h5 class="title">Blinding of participants, personnel, and outcome assessors</h5> <p>Was blinding of individuals involved in the study (participants, personnel, and outcome assessors) to the treatment allocation adequate? </p> <p> <ul id="CD008481-list-0010"> <li> <p>Low risk of bias—any of the following:</p> <ul id="CD008481-list-0011"> <li> <p>No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding. </p> </li> <li> <p>Blinding of participants and key study personnel ensured; unlikely that the blinding could have been broken. </p> </li> <li> <p>Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non‐blinding of others unlikely to introduce bias. </p> </li> </ul> </li> <li> <p>High risk of bias—any of the following:</p> <ul id="CD008481-list-0012"> <li> <p>No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding. </p> </li> <li> <p>Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken. </p> </li> <li> <p>Either participants or some key study personnel were not blinded, and the non‐blinding of others is likely to introduce bias. </p> </li> </ul> </li> <li> <p>Unclear: insufficient information allow conclusion of 'low risk of bias' or 'high risk of bias.' </p> </li> </ul> </p> </section> <section id="CD008481-sec-0046"> <h5 class="title">Incomplete outcome data</h5> <p>Were incomplete outcome data adequately addressed?</p> <p> <ul id="CD008481-list-0013"> <li> <p>Low risk of bias－any of the following:</p> <ul id="CD008481-list-0014"> <li> <p>No missing outcome data.</p> </li> <li> <p>Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias). </p> </li> <li> <p>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. </p> </li> <li> <p>For dichotomous outcomes data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate. </p> </li> <li> <p>For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size. </p> </li> <li> <p>Missing data have been imputed using appropriate method.</p> </li> </ul> </li> <li> <p>High risk of bias－any of the following:</p> <ul id="CD008481-list-0015"> <li> <p>Reason for missing outcome data likely to be related to true outcome, with imbalance in numbers of or reasons for missing data across intervention groups. </p> </li> <li> <p>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate. </p> </li> <li> <p>For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size. </p> </li> <li> <p>'As‐treated' analysis done with substantial departure of the intervention received from that assigned at randomisation. </p> </li> <li> <p>Potentially inappropriate application of simple imputation.</p> </li> </ul> </li> <li> <p>Unclear: insufficient reporting of attrition/exclusions to conclude 'low risk of bias' or 'high risk of bias' </p> </li> </ul> </p> </section> <section id="CD008481-sec-0047"> <h5 class="title">Selective outcome reporting</h5> <p>Are reports of the study free of selective outcome reporting?</p> <p> <ul id="CD008481-list-0016"> <li> <p>Low risk of bias－any of the following:</p> <ul id="CD008481-list-0017"> <li> <p>Study protocol is available and all pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way. </p> </li> <li> <p>Study protocol is not available, but it is clear that published reports include all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon). </p> </li> </ul> </li> <li> <p>High risk of bias－any of the following:</p> <ul id="CD008481-list-0018"> <li> <p>Not all pre‐specified primary outcomes of the study have been reported.</p> </li> <li> <p>One or more primary outcomes are reported using measurements, analysis methods, or subsets of the data (e.g. subscales) that were not pre‐specified. </p> </li> <li> <p>One or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect). </p> </li> <li> <p>One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis. </p> </li> <li> <p>Study report fails to include results for a key outcome that would be expected to have been reported for such a study. </p> </li> </ul> </li> <li> <p>Unclear: information is insufficient to allow investigators to conclude 'low risk of bias' or 'high risk of bias' </p> </li> </ul> </p> </section> <section id="CD008481-sec-0048"> <h5 class="title">Other potential threats to validity</h5> <p>Was the study free from other problems that could put it at risk of bias?</p> <p> <ul id="CD008481-list-0019"> <li> <p>Low risk of bias: Study appears to be free from other sources of bias.</p> </li> <li> <p>High risk of bias: One or more important risks of bias are included (e.g. extreme baseline imbalance). </p> </li> <li> <p>Unclear: Information is insufficient to allow investigators to assess whether there is an important risk of bias. </p> </li> </ul> </p> <p>An overall assessment of the level of bias in the included trials was performed to determine the reliability and validity of the data. </p> </section> </section> <section id="CD008481-sec-0049"> <h4 class="title">Measures of treatment effect</h4> <p>All outcomes were dichotomous; therefore, the measure of treatment effect calculated was risk ratio (RR) with an associated 95% confidence interval (95% CI) using a random‐effects model. A random‐effects model was conducted for all analyses to account for the underlying heterogeneity of included studies, in which different participant populations, antibiotics, and infections were studied. Also, most of the studies were small; therefore, it was thought that a random‐effects model would be less likely to diminish the importance of an observed effect because the weights assigned to each study would be more balanced. </p> </section> <section id="CD008481-sec-0050"> <h4 class="title">Unit of analysis issues</h4> <p>The participant was the unit of analysis. Data from all randomly assigned participants were used for analyses. Scenarios in which censoring or exclusion of data was possible and whether results were presented as the total number of events or the total number of participants with a first event were examined closely. Authors of the studies were contacted regarding any ambiguity. </p> </section> <section id="CD008481-sec-0051"> <h4 class="title">Dealing with missing data</h4> <p>Authors of the studies were contacted via e‐mail to clarify and provide any missing data. </p> </section> <section id="CD008481-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>The I<sup>2</sup> statistic and the Chi<sup>2</sup> test were used to test for heterogeneity in the included studies. The threshold for the I<sup>2</sup> statistic was &gt; 50% for important heterogeneity to be considered. The threshold for the Chi<sup>2</sup> statistic was P &lt; 0.10 for important heterogeneity to be considered. When heterogeneity was detected (Chi<sup>2</sup> test value of P &lt; 0.10 or I<sup>2</sup> &gt; 50%), a random‐effects model was used to confirm whether a statistically significant difference between the effects of continuous infusion and those of intermittent infusion could be noted. Clinical and methodological sources of heterogeneity were investigated, including baseline risk factors for outcome measures, study duration, age, race, and sex distribution of participants across studies. </p> <p>Initially, a fixed‐effect meta‐analysis was planned because the default for all analyses and a random‐effects model would be used only when heterogeneity was detected. However, a random‐effects model was used as the default because a large number of small studies with between‐study heterogeneity (e.g. different infections and antibiotics between studies) were used. Fixed‐effect analyses were conducted to determine if there were differences between models because it is possible that small positive studies may drive the meta‐analysis to look more positive as small studies may be given more weight when a random‐effects model is used. </p> </section> <section id="CD008481-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>Funnel plots were produced to detect potential publication bias. Any asymmetry noted in the plot was investigated to identify possible reasons for the asymmetry (i.e. true heterogeneity of treatment effect, play of chance, poor methodology in included studies). </p> </section> <section id="CD008481-sec-0054"> <h4 class="title">Data synthesis</h4> <p>Review Manager 5 (<a href="./references#CD008481-bbs2-0090" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008. ">RevMan 2008</a>) was used to perform all data syntheses and analyses. Risk ratios for dichotomous clinical outcomes were calculated and are presented with 95% confidence intervals. GRADEpro (<a href="./references#CD008481-bbs2-0075" title="Version 3.2 for Windows. BrozekJ , OxmanA , SchunemannH . GRADEpro (GRADEprofiler).. The Cochrane Collaboration, 2008. ">GRADEpro 2008</a>) was used to generate the 'summary of findings' table. </p> </section> <section id="CD008481-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Any heterogeneity detected was investigated for possible reasons (<a href="./references#CD008481-bbs2-0077" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. British Medical Journal2003;327(7414):557‐60. ">Higgins 2003</a>). Aspects of trials assessed included antibiotic choice, infections being treated, use of other open‐label antibiotics, and dose/duration of antibiotic therapy. A subgroup analysis of trials that included septic participants versus non‐septic participants was conducted to determine whether differences in effect were based on this variable. </p> </section> <section id="CD008481-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were performed for primary outcomes only. Sensitivity analyses were performed to determine the impact of the presence or absence of appropriate allocation concealment procedures on all‐cause mortality and infection recurrence effect estimates. Sensitivity analyses were also performed to determine the impact of trials studying extended interval infusions compared with intermittent infusions and the impact of the use of other open‐label antibiotics in studies. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008481-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008481-sec-0057"></div> <section id="CD008481-sec-0058"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD008481-sec-0087" title="">Characteristics of included studies</a>; <a href="./references#CD008481-sec-0088" title="">Characteristics of excluded studies</a>. </p> <section id="CD008481-sec-0059"> <h4 class="title">Results of the search</h4> <p>The searches conducted in January 2010 identified 2935 records and 6 additional records from other sources. After removal of 1133 duplicate records, 1808 records were screened. The titles and abstracts for these results were screened by four appraisers; initially, 1752 studies were excluded for not meeting the pre‐defined inclusion criteria. The full texts of the remaining 56 potentially eligible studies were retrieved for further assessment. Of 56 potentially eligible studies, 26 studies met the pre–specified inclusion criteria and were included in this review (<a href="#CD008481-fig-0001">Figure 1</a>). Two trials were translated from French into English. However, only a partial translation of 1 trial from Japanese into English could be obtained. An updated search conducted in September 2012 identified 326 records and 3 additional records from other sources. After removal of 102 duplicate records, 227 records were screened and 4 full text articles were retrieved for further assessment. Of the 4 potentially eligible studies, 3 studies were included in this review (<a href="#CD008481-fig-0001">Figure 1</a>). No trials from the updated search required translation into English. A total of 29 studies were included in this review from searches conducted in January 2010 and September 2012. A search of an online clinical trials register (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the Internet identified 8 ongoing studies as of November 2012 that may meet inclusion criteria for this review. </p> <div class="figure" id="CD008481-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Continuous vs intermittent study flow diagram." data-id="CD008481-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Continuous vs intermittent study flow diagram.</p> </div> </div> </div> </section> <section id="CD008481-sec-0060"> <h4 class="title">Included studies</h4> <p>Of the 29 included studies, 25 studies compared continuous antibiotic infusions with traditional intermittent infusions, and 4 studies compared extended antibiotic infusions with intermittent infusions. Hospitalised patients were studied in the 29 included trials, and 19 of these trials studied patients admitted to a critical care unit. The population size of each study ranged from 7 to 262 patients; 4 studies had a study sample size greater than 100 patients. The studies included adults between the ages of 18 and 80 years, with the exception of one trial (<a href="./references#CD008481-bbs2-0008" title="FeldR , ValdiviesoM , BodeyGP , RodriguezV . A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences1977;274(2):179‐88. ">Feld 1977</a>), which included patients aged 15 years and older. This trial was included in the analysis because the median participant age was 43 to 46 years; therefore, it was thought that very few patients younger than 18 years participated in the study. The percentage of males in the included studies ranged from 43% to 82%.  </p> <p>Types of infections studied in the included trials were pneumonia (n = 16), septicemia (n = 13), urinary tract infection (n = 3), skin and soft tissue infection (n = 2), peritonitis (n = 2), acute exacerbation of chronic obstructive pulmonary disease (n = 2), acute exacerbation of chronic bronchitis (n = 1), fever of unknown origin (n = 1), cholangitis (n = 1), sinusitis (n = 1), perirectal infection (n = 1), intra–abdominal or periappendiceal abscess (n = 1), complicated perforated diverticulitis (n = 1), shock lung (n = 1), endocarditis (n = 1), melioidosis (n = 1), catheter‐related infection (n = 1), mediastinitis (n = 1), post‐operative surgical infection (n = 1), and meningitis or central nervous system infection (n = 1).  Organisms isolated included <i>Enterococcus faecalis</i> , <i>Enterococcus faecium,</i> coagulase‐negative<i>Staphylococcus</i> (CoNS), <i>Staphylococcus aureus,</i> methicillin–resistant<i>Staphylococcus aureus</i> (MRSA), <i>Burkholderia</i> , <i>Escherichia coli</i> , <i>Klebsiella pneumoniae, Pseudomonas aeruginosa,</i> Enterobacteriaceae, <i>Proteus mirabilis</i> , <i>Citrobacter</i> , <i>Serratia marcescens</i> , <i>Acinetobacter</i> , <i>Clostridium</i> , <i>Haemophilus influenzae</i> , <i>Aeromonas</i> , <i>Moraxella catarrhalis</i> , <i>Morganella morganii, Enterobacter, Salmonella</i> , <i>Streptococcus viridans</i> , <i>Streptococcus milleri, Streptococcus mitis, Streptococcus pneumoniae, Stenotrophomonas, Bacteroides</i> , and <i>Peptostreptococcus</i>. Antibiotics studied included ceftazidime (n = 8), piperacillin‐tazobactam (n = 5), meropenem (n = 3), tobramycin (n = 2), piperacillin (n = 1), linezolid (n = 1), carbenicillin (n = 1), cefamandole (n = 1), temocillin (n = 1), sisomicin (n = 1), cefepime (n = 1), cefoperazone (n = 1), ceftriaxone (n = 1), imipenem (n = 1), cefotaxime (n = 1), gentamicin (n = 1), and vancomycin (n = 1). Open–label antibiotics were permitted in 17 studies, although the remaining included studies did not indicate whether any additional antibiotics were permitted. Antibiotic treatment duration ranged from 4 to 14 days. Follow‐up duration ranged from 24 hours to 28 days but was not reported in 18 studies. </p> <p>Of studies meeting inclusion criteria, 3 studies (<a href="./references#CD008481-bbs2-0014" title="LipmanJ , GomersallCD , GinT , JoyntGM , YoungRJ . Continuous infusion ceftazidime in intensive care: a randomized controlled trial. Journal of Antimicrobial Chemotherapy1999;43(2):309‐11. ">Lipman 1999</a>; <a href="./references#CD008481-bbs2-0016" title="NicolauDP , McNabbJ , LacyMK , LiJ , QuintilianiR , NightingaleCH . Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clinical Drug Investigation1999;18(2):133‐9. ">Nicolau 1999a</a>; <a href="./references#CD008481-bbs2-0017" title="NicolauDP , LacyMK , McNabbJ , QuintilianiR , NightingaleCH . Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infectious Diseases in Clinical Practice1999;8(1):45‐9. ">Nicolau 1999b</a>) did not report any outcome data. One study (<a href="./references#CD008481-bbs2-0003" title="BodeyGP , KetchelSJ , RodriguezV . A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. American Journal of Medicine1979;67(4):608‐16. ">Bodey 1979</a>) reported outcomes expressed as episodes and not by participant. This unit of analysis issue could not be reconciled. Therefore, 4 studies that met inclusion criteria did not contribute data to this meta‐analysis. </p> </section> <section id="CD008481-sec-0061"> <h4 class="title">Excluded studies</h4> <p>Of 60 potentially eligible studies, 31 were excluded after closer examination by 4 independent study appraisers. Studies excluded were cross‐over studies (n = 10), were not randomised (n = 9), used prophylactic antibiotics (n = 3), and included healthy volunteers (n = 2), pharmacoeconomic or cost‐effectiveness analyses (n = 2), pharmacokinetic/pharmacodynamic analyses of already included studies (n = 1), letters to the editor (n = 1), case reports (n = 1), uncontrolled (n = 1), or preliminary analyses of an already included study (n = 1). </p> </section> </section> <section id="CD008481-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>Most included studies were judged to be at unclear or high risk of bias with regard to randomisation sequence generation, allocation concealment, blinding, management of incomplete outcome data, selective outcome reporting, and other potential threats to validity (86%, 76%, 97%, 69%, 76%, and 90% of studies, respectively). No studies were judged to be at low risk of bias for all methodological quality items assessed. </p> <p>See 'Risk of bias' tables and 'Risk of bias' graphs (<a href="#CD008481-fig-0002">Figure 2</a>, <a href="#CD008481-fig-0003">Figure 3</a>) for additional details regarding evaluation of the included studies. </p> <div class="figure" id="CD008481-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD008481-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <div class="figure" id="CD008481-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD008481-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD008481-sec-0063"> <h4 class="title">Allocation</h4> <p><b>Generation of randomisation sequence</b> </p> <p>Four trials (<a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0014" title="LipmanJ , GomersallCD , GinT , JoyntGM , YoungRJ . Continuous infusion ceftazidime in intensive care: a randomized controlled trial. Journal of Antimicrobial Chemotherapy1999;43(2):309‐11. ">Lipman 1999</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>) adequately described generation of allocation sequence procedures and were judged to be at low risk of bias. Four trials (<a href="./references#CD008481-bbs2-0017" title="NicolauDP , LacyMK , McNabbJ , QuintilianiR , NightingaleCH . Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infectious Diseases in Clinical Practice1999;8(1):45‐9. ">Nicolau 1999b</a>; <a href="./references#CD008481-bbs2-0018" title="NicolauDP , McNabbJ , LacyMK , QuintilianiR , NightingaleCH . Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. International Journal of Antimicrobial Agents2001;17(6):497‐504. ">Nicolau 2001</a>; <a href="./references#CD008481-bbs2-0021" title="RafatiMR , RouiniMR , MojtahedzadehM , NajafiA , TavakoliH , GholamiK , FazeliMR . Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. International Journal of Antimicrobial Agents2006;28(2):122‐7. ">Rafati 2006</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>) did not describe randomisation methods or generation of allocation sequence methods and were judged to have an unclear risk of bias. The remaining 21 studies were randomised, but randomisation methods were not reported or could not be translated into English, and these studies were judged to have an unclear risk of bias. For additional details, refer to information presented in 'Risk of bias' tables. </p> <p><b>Allocation concealment</b> </p> <p>Six studies (<a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>) used sealed, opaque envelopes to conceal randomisation allocation and were judged to be at low risk of bias. Five trials (<a href="./references#CD008481-bbs2-0001" title="AdembriC , FallaniS , CassettaMI , ArrigucciS , OttavianoA , PecileP , MazzeiT , DeGaudioR , NovelliA . Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. International Journal of Antimicrobial Agents2008;31(2):122‐9. ">Adembri 2008</a>; <a href="./references#CD008481-bbs2-0003" title="BodeyGP , KetchelSJ , RodriguezV . A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. American Journal of Medicine1979;67(4):608‐16. ">Bodey 1979</a>; <a href="./references#CD008481-bbs2-0004" title="BuckC , BertramN , AckermannT , SauerbruchT , DerendorfH , PaarWD . Pharmacokinetics of piperacillin‐tazobactam: intermittent dosing versus continuous infusion. International Journal of Antimicrobial Agents2005;25(1):62‐7. ">Buck 2005</a>; <a href="./references#CD008481-bbs2-0009" title="FeldR , RachlisA , TuffnellPG , DuncanI , MoranL , PinfoldP , DeBoerG . Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Archives of Internal Medicine1984;144(5):1005‐10. ">Feld 1984</a>; <a href="./references#CD008481-bbs2-0026" title="SakkaSG , GlaunerAK , BulittaJB , Kinzig‐SchippersM , PfisterW , DrusanoGL , SorgelF . Population pharmacokinetics and pharmacodynamics of continuous versus short‐term infusion of imipenem‐cilastatin in critically ill patients in a randomized, controlled trial. Antimicrobial Agents and Chemotherapy2007;51(9):3304‐10. ">Sakka 2007</a>) used sealed envelopes to conceal randomisation allocation, but opacity of envelopes was not described, and these studies were judged to be at unclear risk of bias. Allocation concealment was not clear in 1 study (<a href="./references#CD008481-bbs2-0019" title="OkimotoN , IshigaM , NanbaF , KibayashiT , KishimotoM , KuriharaT , HondaY , AsaokaN , TamadaS . Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly (Japanese). Nihon Kokyuki Gakkai Zasshi2009;47(7):553‐7. ">Okimoto 2009</a>) because only a partial translation from Japanese into English was available. The remaining 17 studies did not describe allocation concealment methods and were judged to be at unclear risk of bias. For additional details, refer to information presented in 'Risk of bias' tables. </p> </section> <section id="CD008481-sec-0064"> <h4 class="title">Blinding</h4> <p>Fourteen studies (<a href="./references#CD008481-bbs2-0001" title="AdembriC , FallaniS , CassettaMI , ArrigucciS , OttavianoA , PecileP , MazzeiT , DeGaudioR , NovelliA . Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. International Journal of Antimicrobial Agents2008;31(2):122‐9. ">Adembri 2008</a>; <a href="./references#CD008481-bbs2-0004" title="BuckC , BertramN , AckermannT , SauerbruchT , DerendorfH , PaarWD . Pharmacokinetics of piperacillin‐tazobactam: intermittent dosing versus continuous infusion. International Journal of Antimicrobial Agents2005;25(1):62‐7. ">Buck 2005</a>; <a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>; <a href="./references#CD008481-bbs2-0015" title="LubaschA , LuckS , HartmutL , MauchH , LorenzJ , BolcskeiP , WelteT . Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. Journal of Antimicrobial Chemotherapy2003;51:659‐64. ">Lubasch 2003</a>; <a href="./references#CD008481-bbs2-0018" title="NicolauDP , McNabbJ , LacyMK , QuintilianiR , NightingaleCH . Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. International Journal of Antimicrobial Agents2001;17(6):497‐504. ">Nicolau 2001</a>; <a href="./references#CD008481-bbs2-0020" title="PedeboscqS , DubauB , FrappierS , HernandezV , VeyssieresD , WinnockS , PometanJP . Comparison of 2 administration protocols (continuous or discontinuous) of a time‐dependent antibiotic, Tazocin (French). Pathologie Biologie (Paris)2001;49(7):540‐7. ">Pedeboscq 2001</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>) were not blind and were judged to be at high risk of bias. One study (<a href="./references#CD008481-bbs2-0016" title="NicolauDP , McNabbJ , LacyMK , LiJ , QuintilianiR , NightingaleCH . Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clinical Drug Investigation1999;18(2):133‐9. ">Nicolau 1999a</a>) was single blind and was judged to be at high risk of bias. Another study (<a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>) was double blind and was judged to be at low risk of bias. Blinding was not clear in 1 study (<a href="./references#CD008481-bbs2-0019" title="OkimotoN , IshigaM , NanbaF , KibayashiT , KishimotoM , KuriharaT , HondaY , AsaokaN , TamadaS . Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly (Japanese). Nihon Kokyuki Gakkai Zasshi2009;47(7):553‐7. ">Okimoto 2009</a>) because only a partial translation from Japanese into English was available. The remaining 12 studies did not comment on blinding and were judged to be at unclear risk of bias. For additional details, refer to information presented in 'Risk of bias' tables. </p> </section> <section id="CD008481-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>Participants were lost to follow‐up or were censored in 12 trials (<a href="./references#CD008481-bbs2-0002" title="AngusBJ , SmithMD , SuputtamongkolY , MattieH , WalshAL , WuthiekanunV , ChaowagulW , WhiteNJ . Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology2000;49(5):445‐52. ">Angus 2000</a>; <a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0008" title="FeldR , ValdiviesoM , BodeyGP , RodriguezV . A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences1977;274(2):179‐88. ">Feld 1977</a>; <a href="./references#CD008481-bbs2-0009" title="FeldR , RachlisA , TuffnellPG , DuncanI , MoranL , PinfoldP , DeBoerG . Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Archives of Internal Medicine1984;144(5):1005‐10. ">Feld 1984</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0011" title="HanesSD , WoodGC , HerringV , CroceMA , FabianTC , PritchardE , BoucherBA . Intermittent and continuous ceftazidime infusion for critically ill trauma patients. The American Journal of Surgery2000;179(6):436‐40. ">Hanes 2000</a>; <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>; <a href="./references#CD008481-bbs2-0015" title="LubaschA , LuckS , HartmutL , MauchH , LorenzJ , BolcskeiP , WelteT . Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. Journal of Antimicrobial Chemotherapy2003;51:659‐64. ">Lubasch 2003</a>; <a href="./references#CD008481-bbs2-0016" title="NicolauDP , McNabbJ , LacyMK , LiJ , QuintilianiR , NightingaleCH . Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clinical Drug Investigation1999;18(2):133‐9. ">Nicolau 1999a</a>; <a href="./references#CD008481-bbs2-0018" title="NicolauDP , McNabbJ , LacyMK , QuintilianiR , NightingaleCH . Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. International Journal of Antimicrobial Agents2001;17(6):497‐504. ">Nicolau 2001</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>) and were judged to be at unclear or high risk of bias. One trial (<a href="./references#CD008481-bbs2-0001" title="AdembriC , FallaniS , CassettaMI , ArrigucciS , OttavianoA , PecileP , MazzeiT , DeGaudioR , NovelliA . Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. International Journal of Antimicrobial Agents2008;31(2):122‐9. ">Adembri 2008</a>) included participants who did not complete the study and was judged to be at unclear risk of bias. Two studies (<a href="./references#CD008481-bbs2-0003" title="BodeyGP , KetchelSJ , RodriguezV . A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. American Journal of Medicine1979;67(4):608‐16. ">Bodey 1979</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>) did not report all pre–specified outcomes for all participants and were judged to be at high risk of bias. Nine studies (<a href="./references#CD008481-bbs2-0004" title="BuckC , BertramN , AckermannT , SauerbruchT , DerendorfH , PaarWD . Pharmacokinetics of piperacillin‐tazobactam: intermittent dosing versus continuous infusion. International Journal of Antimicrobial Agents2005;25(1):62‐7. ">Buck 2005</a>; <a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0012" title="LagastH , Meunier‐CarpentierF , KlasterskyJ . Treatment of gram‐negative bacillary septicemia with cefoperazone. European Journal of Clinical Microbiology1983;2(6):554‐8. ">Lagast 1983</a>; <a href="./references#CD008481-bbs2-0017" title="NicolauDP , LacyMK , McNabbJ , QuintilianiR , NightingaleCH . Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infectious Diseases in Clinical Practice1999;8(1):45‐9. ">Nicolau 1999b</a>; <a href="./references#CD008481-bbs2-0019" title="OkimotoN , IshigaM , NanbaF , KibayashiT , KishimotoM , KuriharaT , HondaY , AsaokaN , TamadaS . Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly (Japanese). Nihon Kokyuki Gakkai Zasshi2009;47(7):553‐7. ">Okimoto 2009</a>; <a href="./references#CD008481-bbs2-0021" title="RafatiMR , RouiniMR , MojtahedzadehM , NajafiA , TavakoliH , GholamiK , FazeliMR . Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. International Journal of Antimicrobial Agents2006;28(2):122‐7. ">Rafati 2006</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>) yielded complete outcome data and were judged to be at low risk of bias. Five studies (<a href="./references#CD008481-bbs2-0014" title="LipmanJ , GomersallCD , GinT , JoyntGM , YoungRJ . Continuous infusion ceftazidime in intensive care: a randomized controlled trial. Journal of Antimicrobial Chemotherapy1999;43(2):309‐11. ">Lipman 1999</a>; <a href="./references#CD008481-bbs2-0020" title="PedeboscqS , DubauB , FrappierS , HernandezV , VeyssieresD , WinnockS , PometanJP . Comparison of 2 administration protocols (continuous or discontinuous) of a time‐dependent antibiotic, Tazocin (French). Pathologie Biologie (Paris)2001;49(7):540‐7. ">Pedeboscq 2001</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>;<a href="./references#CD008481-bbs2-0026" title="SakkaSG , GlaunerAK , BulittaJB , Kinzig‐SchippersM , PfisterW , DrusanoGL , SorgelF . Population pharmacokinetics and pharmacodynamics of continuous versus short‐term infusion of imipenem‐cilastatin in critically ill patients in a randomized, controlled trial. Antimicrobial Agents and Chemotherapy2007;51(9):3304‐10. ">Sakka 2007</a>; <a href="./references#CD008481-bbs2-0028" title="WrightJP , PotgieterPD , ForderAA , BothaP , BrinkworthG , ElishaG , FergusonAD . Gentamicin and penicillin in the treatment of severe respiratory infections. South African Medical Journal1979;55(6):197‐200. ">Wright 1979</a>) did not report on attrition bias and were judged to be at unclear risk of bias. For additional details, refer to information presented in 'Risk of bias' tables. </p> <p>The corresponding authors of 25 studies were contacted via e‐mail to clarify and provide missing outcome data. Nine authors replied with the requested missing data, which were incorporated into the analyses. Five authors stated that the requested missing data were no longer available, and the remaining authors did not respond. </p> <p>No authors of the 8 ongoing studies were contacted, and no data from these unpublished or ongoing trials were included, because it was not clear from the current information provided whether these trials will meet inclusion criteria for this review. When the full texts of these studies become available, they will be considered for future updates. </p> <p>It is important to note that a substantial amount of information was not available for the pre‐specified outcome measures of this review. Data from all 29 RCTS were not reported for any outcome measures. See table below. </p> <p> <div class="table" id="CD008481-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of trials reporting outcomes (of a total of 29 possible trials)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection recurrence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical cure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Super‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawal due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD008481-sec-0066"> <h4 class="title">Selective reporting</h4> <p>Seven studies (<a href="./references#CD008481-bbs2-0001" title="AdembriC , FallaniS , CassettaMI , ArrigucciS , OttavianoA , PecileP , MazzeiT , DeGaudioR , NovelliA . Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. International Journal of Antimicrobial Agents2008;31(2):122‐9. ">Adembri 2008</a>; <a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0008" title="FeldR , ValdiviesoM , BodeyGP , RodriguezV . A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences1977;274(2):179‐88. ">Feld 1977</a>; <a href="./references#CD008481-bbs2-0015" title="LubaschA , LuckS , HartmutL , MauchH , LorenzJ , BolcskeiP , WelteT . Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. Journal of Antimicrobial Chemotherapy2003;51:659‐64. ">Lubasch 2003</a>; <a href="./references#CD008481-bbs2-0020" title="PedeboscqS , DubauB , FrappierS , HernandezV , VeyssieresD , WinnockS , PometanJP . Comparison of 2 administration protocols (continuous or discontinuous) of a time‐dependent antibiotic, Tazocin (French). Pathologie Biologie (Paris)2001;49(7):540‐7. ">Pedeboscq 2001</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>) reported all pre–specified outcomes and were judged to be at low risk of bias. Seven studies (<a href="./references#CD008481-bbs2-0002" title="AngusBJ , SmithMD , SuputtamongkolY , MattieH , WalshAL , WuthiekanunV , ChaowagulW , WhiteNJ . Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology2000;49(5):445‐52. ">Angus 2000</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0014" title="LipmanJ , GomersallCD , GinT , JoyntGM , YoungRJ . Continuous infusion ceftazidime in intensive care: a randomized controlled trial. Journal of Antimicrobial Chemotherapy1999;43(2):309‐11. ">Lipman 1999</a>; <a href="./references#CD008481-bbs2-0016" title="NicolauDP , McNabbJ , LacyMK , LiJ , QuintilianiR , NightingaleCH . Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clinical Drug Investigation1999;18(2):133‐9. ">Nicolau 1999a</a>; <a href="./references#CD008481-bbs2-0026" title="SakkaSG , GlaunerAK , BulittaJB , Kinzig‐SchippersM , PfisterW , DrusanoGL , SorgelF . Population pharmacokinetics and pharmacodynamics of continuous versus short‐term infusion of imipenem‐cilastatin in critically ill patients in a randomized, controlled trial. Antimicrobial Agents and Chemotherapy2007;51(9):3304‐10. ">Sakka 2007</a>; <a href="./references#CD008481-bbs2-0028" title="WrightJP , PotgieterPD , ForderAA , BothaP , BrinkworthG , ElishaG , FergusonAD . Gentamicin and penicillin in the treatment of severe respiratory infections. South African Medical Journal1979;55(6):197‐200. ">Wright 1979</a>) reported outcomes that were not pre–specified and were judged to be at unclear or high risk of bias. Five studies (<a href="./references#CD008481-bbs2-0011" title="HanesSD , WoodGC , HerringV , CroceMA , FabianTC , PritchardE , BoucherBA . Intermittent and continuous ceftazidime infusion for critically ill trauma patients. The American Journal of Surgery2000;179(6):436‐40. ">Hanes 2000</a>; <a href="./references#CD008481-bbs2-0012" title="LagastH , Meunier‐CarpentierF , KlasterskyJ . Treatment of gram‐negative bacillary septicemia with cefoperazone. European Journal of Clinical Microbiology1983;2(6):554‐8. ">Lagast 1983</a>; <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>; <a href="./references#CD008481-bbs2-0017" title="NicolauDP , LacyMK , McNabbJ , QuintilianiR , NightingaleCH . Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infectious Diseases in Clinical Practice1999;8(1):45‐9. ">Nicolau 1999b</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>) did not report all pre–specified outcomes and were judged to be at unclear or high risk of bias. Three studies (<a href="./references#CD008481-bbs2-0003" title="BodeyGP , KetchelSJ , RodriguezV . A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. American Journal of Medicine1979;67(4):608‐16. ">Bodey 1979</a>; <a href="./references#CD008481-bbs2-0009" title="FeldR , RachlisA , TuffnellPG , DuncanI , MoranL , PinfoldP , DeBoerG . Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Archives of Internal Medicine1984;144(5):1005‐10. ">Feld 1984</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>) did not report the total numbers of participants or participants in each group and were judged to be at high or unclear risk of bias. Five studies (<a href="./references#CD008481-bbs2-0018" title="NicolauDP , McNabbJ , LacyMK , QuintilianiR , NightingaleCH . Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. International Journal of Antimicrobial Agents2001;17(6):497‐504. ">Nicolau 2001</a>; <a href="./references#CD008481-bbs2-0021" title="RafatiMR , RouiniMR , MojtahedzadehM , NajafiA , TavakoliH , GholamiK , FazeliMR . Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. International Journal of Antimicrobial Agents2006;28(2):122‐7. ">Rafati 2006</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>) did not describe methods, including outcomes, and were judged to be at unclear risk of bias. One study (<a href="./references#CD008481-bbs2-0004" title="BuckC , BertramN , AckermannT , SauerbruchT , DerendorfH , PaarWD . Pharmacokinetics of piperacillin‐tazobactam: intermittent dosing versus continuous infusion. International Journal of Antimicrobial Agents2005;25(1):62‐7. ">Buck 2005</a>) did not assess clinical outcomes and was judged to be at unclear risk of bias. Selective reporting was not clear in 1 study (<a href="./references#CD008481-bbs2-0019" title="OkimotoN , IshigaM , NanbaF , KibayashiT , KishimotoM , KuriharaT , HondaY , AsaokaN , TamadaS . Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly (Japanese). Nihon Kokyuki Gakkai Zasshi2009;47(7):553‐7. ">Okimoto 2009</a>) because only a partial translation from Japanese into English was available. For additional details, refer to information presented in 'Risk of bias' tables. </p> </section> <section id="CD008481-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>No other potential sources of bias were identified in 3 studies (<a href="./references#CD008481-bbs2-0002" title="AngusBJ , SmithMD , SuputtamongkolY , MattieH , WalshAL , WuthiekanunV , ChaowagulW , WhiteNJ . Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology2000;49(5):445‐52. ">Angus 2000</a>; <a href="./references#CD008481-bbs2-0008" title="FeldR , ValdiviesoM , BodeyGP , RodriguezV . A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences1977;274(2):179‐88. ">Feld 1977</a>; <a href="./references#CD008481-bbs2-0021" title="RafatiMR , RouiniMR , MojtahedzadehM , NajafiA , TavakoliH , GholamiK , FazeliMR . Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. International Journal of Antimicrobial Agents2006;28(2):122‐7. ">Rafati 2006</a>), which were judged to be at low risk of bias. Other potential sources of bias were not clear in 1 study (<a href="./references#CD008481-bbs2-0019" title="OkimotoN , IshigaM , NanbaF , KibayashiT , KishimotoM , KuriharaT , HondaY , AsaokaN , TamadaS . Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly (Japanese). Nihon Kokyuki Gakkai Zasshi2009;47(7):553‐7. ">Okimoto 2009</a>) because only a partial translation from Japanese into English was available. The remaining 25 studies included participant baseline imbalances, unclear use of open–label antibiotics, or pharmaceutical company funding and were judged to be at unclear or high risk of bias. For additional details, refer to information presented in 'Risk of bias' tables. </p> </section> </section> <section id="CD008481-sec-0068"> <h3 class="title" id="CD008481-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD008481-tbl-0001"><b>Summary of findings for the main comparison</b> Continuous versus Intermittent Antibiotic Infusions for Treatment of Severe Bacterial Infections</a> </p> <p>Intention‐to‐treat analyses were conducted for all outcomes using the total numbers of participants randomly assigned to each intervention for each included study. All analyses were conduced using a random‐effects model and a fixed‐effect model. One difference between the 2 models in the subgroup analysis of septic versus non‐septic participants reporting clinical cure data was noted. However, no differences between the 2 models were observed in all other analyses, suggesting no bias due to small study effects. </p> <p>Worst‐case scenarios were conducted for primary and secondary outcomes for participants lost to follow‐up or censored. Analyses were conducted only when exact numbers of missing participants were known. </p> <p><b>All–cause mortality</b> (<a href="./references#CD008481-fig-0008" title="">Analysis 1.1</a>) </p> <p>Nineteen studies reported mortality data (<a href="./references#CD008481-bbs2-0001" title="AdembriC , FallaniS , CassettaMI , ArrigucciS , OttavianoA , PecileP , MazzeiT , DeGaudioR , NovelliA . Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. International Journal of Antimicrobial Agents2008;31(2):122‐9. ">Adembri 2008</a>; <a href="./references#CD008481-bbs2-0002" title="AngusBJ , SmithMD , SuputtamongkolY , MattieH , WalshAL , WuthiekanunV , ChaowagulW , WhiteNJ . Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology2000;49(5):445‐52. ">Angus 2000</a>; <a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0008" title="FeldR , ValdiviesoM , BodeyGP , RodriguezV . A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences1977;274(2):179‐88. ">Feld 1977</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0012" title="LagastH , Meunier‐CarpentierF , KlasterskyJ . Treatment of gram‐negative bacillary septicemia with cefoperazone. European Journal of Clinical Microbiology1983;2(6):554‐8. ">Lagast 1983</a>; <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>; <a href="./references#CD008481-bbs2-0020" title="PedeboscqS , DubauB , FrappierS , HernandezV , VeyssieresD , WinnockS , PometanJP . Comparison of 2 administration protocols (continuous or discontinuous) of a time‐dependent antibiotic, Tazocin (French). Pathologie Biologie (Paris)2001;49(7):540‐7. ">Pedeboscq 2001</a>; <a href="./references#CD008481-bbs2-0021" title="RafatiMR , RouiniMR , MojtahedzadehM , NajafiA , TavakoliH , GholamiK , FazeliMR . Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. International Journal of Antimicrobial Agents2006;28(2):122‐7. ">Rafati 2006</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0026" title="SakkaSG , GlaunerAK , BulittaJB , Kinzig‐SchippersM , PfisterW , DrusanoGL , SorgelF . Population pharmacokinetics and pharmacodynamics of continuous versus short‐term infusion of imipenem‐cilastatin in critically ill patients in a randomized, controlled trial. Antimicrobial Agents and Chemotherapy2007;51(9):3304‐10. ">Sakka 2007</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>; <a href="./references#CD008481-bbs2-0028" title="WrightJP , PotgieterPD , ForderAA , BothaP , BrinkworthG , ElishaG , FergusonAD . Gentamicin and penicillin in the treatment of severe respiratory infections. South African Medical Journal1979;55(6):197‐200. ">Wright 1979</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). No statistically significant differences in all–cause mortality were noted when time–dependent antibiotics and concentration–dependent antibiotics were analysed together (n = 1241, pooled relative risk (RR) 0.89, 95% CI 0.67 to 1.20, P = 0.45). No evidence of statistical heterogeneity was found (Chi<sup>2</sup> = 13.86, degrees of freedom (df) = 15, P = 0.54; I<sup>2</sup> = 0%). </p> <p>Seventeen studies compared time–dependent antibiotics (<a href="./references#CD008481-bbs2-0001" title="AdembriC , FallaniS , CassettaMI , ArrigucciS , OttavianoA , PecileP , MazzeiT , DeGaudioR , NovelliA . Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. International Journal of Antimicrobial Agents2008;31(2):122‐9. ">Adembri 2008</a>; <a href="./references#CD008481-bbs2-0002" title="AngusBJ , SmithMD , SuputtamongkolY , MattieH , WalshAL , WuthiekanunV , ChaowagulW , WhiteNJ . Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology2000;49(5):445‐52. ">Angus 2000</a>; <a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0012" title="LagastH , Meunier‐CarpentierF , KlasterskyJ . Treatment of gram‐negative bacillary septicemia with cefoperazone. European Journal of Clinical Microbiology1983;2(6):554‐8. ">Lagast 1983</a>; <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>; <a href="./references#CD008481-bbs2-0020" title="PedeboscqS , DubauB , FrappierS , HernandezV , VeyssieresD , WinnockS , PometanJP . Comparison of 2 administration protocols (continuous or discontinuous) of a time‐dependent antibiotic, Tazocin (French). Pathologie Biologie (Paris)2001;49(7):540‐7. ">Pedeboscq 2001</a>; <a href="./references#CD008481-bbs2-0021" title="RafatiMR , RouiniMR , MojtahedzadehM , NajafiA , TavakoliH , GholamiK , FazeliMR . Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. International Journal of Antimicrobial Agents2006;28(2):122‐7. ">Rafati 2006</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0026" title="SakkaSG , GlaunerAK , BulittaJB , Kinzig‐SchippersM , PfisterW , DrusanoGL , SorgelF . Population pharmacokinetics and pharmacodynamics of continuous versus short‐term infusion of imipenem‐cilastatin in critically ill patients in a randomized, controlled trial. Antimicrobial Agents and Chemotherapy2007;51(9):3304‐10. ">Sakka 2007</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). No statistically significant differences in all–cause mortality were reported with time–dependent antibiotics (n = 1085, RR 0.87, 95% CI 0.62 to 1.22, P = 0.42).  No evidence of statistical heterogeneity was obtained (Chi<sup>2</sup> = 13.47, df = 13, P = 0.41; I<sup>2</sup> = 4%). </p> <p>Two studies compared concentration–dependent antibiotics (<a href="./references#CD008481-bbs2-0008" title="FeldR , ValdiviesoM , BodeyGP , RodriguezV . A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences1977;274(2):179‐88. ">Feld 1977</a>; <a href="./references#CD008481-bbs2-0028" title="WrightJP , PotgieterPD , ForderAA , BothaP , BrinkworthG , ElishaG , FergusonAD . Gentamicin and penicillin in the treatment of severe respiratory infections. South African Medical Journal1979;55(6):197‐200. ">Wright 1979</a>). No statistically significant differences in all–cause mortality were found with concentration–dependent antibiotics (n = 156, RR 1.10, 95% CI 0.50 to 2.40, P = 0.82). No evidence of statistical heterogeneity was noted (Chi<sup>2</sup> = 0.09, df = 1, P = 0.76; I<sup>2</sup> = 0%). </p> <p>When the worst–case scenario was calculated for time‐dependent and concentration‐dependent antibiotics, when all missing participants were assumed to have died, no statistically significant differences in all–cause mortality were observed (n = 1241, RR 0.94, 95% CI 0.80 to 1.11, P = 0.49). </p> <p><b>Infection recurrence within 14 days of resolution of primary infection</b> (<a href="./references#CD008481-fig-0009" title="">Analysis 1.2</a>) </p> <p>Eight studies reported infection recurrence data; all of these trials compared time–dependent antibiotics (<a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0012" title="LagastH , Meunier‐CarpentierF , KlasterskyJ . Treatment of gram‐negative bacillary septicemia with cefoperazone. European Journal of Clinical Microbiology1983;2(6):554‐8. ">Lagast 1983</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). No statistically significant differences in infection recurrence (n = 398, RR 1.22, 95% CI 0.35 to 4.19, P = 0.76) were described, and no evidence of statistical heterogeneity was found (Chi<sup>2</sup> = 0.37, df = 2, P = 0.83; I<sup>2</sup> = 0%). </p> <p>When the worst–case scenario was calculated for time‐dependent antibiotics, and when all missing participants were assumed to have infection recurrence, no statistically significant differences in infection recurrence were observed (n = 398, RR 0.88, 95% CI 0.46 to 1.66, P = 0.69). </p> <p><b>Clinical cure</b> (<a href="./references#CD008481-fig-0010" title="">Analysis 1.3</a>) </p> <p>Fifteen studies reported clinical cure; all of these studies compared time–dependent antibiotics (<a href="./references#CD008481-bbs2-0001" title="AdembriC , FallaniS , CassettaMI , ArrigucciS , OttavianoA , PecileP , MazzeiT , DeGaudioR , NovelliA . Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. International Journal of Antimicrobial Agents2008;31(2):122‐9. ">Adembri 2008</a>; <a href="./references#CD008481-bbs2-0004" title="BuckC , BertramN , AckermannT , SauerbruchT , DerendorfH , PaarWD . Pharmacokinetics of piperacillin‐tazobactam: intermittent dosing versus continuous infusion. International Journal of Antimicrobial Agents2005;25(1):62‐7. ">Buck 2005</a>; <a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>; <a href="./references#CD008481-bbs2-0015" title="LubaschA , LuckS , HartmutL , MauchH , LorenzJ , BolcskeiP , WelteT . Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. Journal of Antimicrobial Chemotherapy2003;51:659‐64. ">Lubasch 2003</a>; <a href="./references#CD008481-bbs2-0018" title="NicolauDP , McNabbJ , LacyMK , QuintilianiR , NightingaleCH . Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. International Journal of Antimicrobial Agents2001;17(6):497‐504. ">Nicolau 2001</a>; <a href="./references#CD008481-bbs2-0019" title="OkimotoN , IshigaM , NanbaF , KibayashiT , KishimotoM , KuriharaT , HondaY , AsaokaN , TamadaS . Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly (Japanese). Nihon Kokyuki Gakkai Zasshi2009;47(7):553‐7. ">Okimoto 2009</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>). No statistically significant differences in clinical cure were reported (n = 975, RR 1.00, 95% CI 0.93 to 1.08, P = 0.98). No evidence of statistical heterogeneity was found (Chi<sup>2</sup> = 13.72, df = 14, P = 0.47; I<sup>2</sup> = 0%). </p> <p>A worst‐case scenario is not estimable because it is already assumed that all missing participants did not attain clinical cure. </p> <p><b>Superinfections post–therapy</b> (<a href="./references#CD008481-fig-0011" title="">Analysis 1.4</a>) </p> <p>Twelve studies reported secondary super‐infections post–therapy (<a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0008" title="FeldR , ValdiviesoM , BodeyGP , RodriguezV . A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences1977;274(2):179‐88. ">Feld 1977</a>; <a href="./references#CD008481-bbs2-0009" title="FeldR , RachlisA , TuffnellPG , DuncanI , MoranL , PinfoldP , DeBoerG . Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Archives of Internal Medicine1984;144(5):1005‐10. ">Feld 1984</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0011" title="HanesSD , WoodGC , HerringV , CroceMA , FabianTC , PritchardE , BoucherBA . Intermittent and continuous ceftazidime infusion for critically ill trauma patients. The American Journal of Surgery2000;179(6):436‐40. ">Hanes 2000</a>; <a href="./references#CD008481-bbs2-0018" title="NicolauDP , McNabbJ , LacyMK , QuintilianiR , NightingaleCH . Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. International Journal of Antimicrobial Agents2001;17(6):497‐504. ">Nicolau 2001</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). No statistically significant differences in superinfections post–therapy when time–dependent antibiotics and concentration–dependent antibiotics were analysed together (n = 813, RR 1.08, 95% CI 0.60 to 1.94, P = 0.79). No evidence of statistical heterogeneity was found (Chi<sup>2</sup> = 3.64, df = 6, P = 0.73; I<sup>2</sup> = 0%). </p> <p>Ten studies reported secondary super‐infections in studies comparing time–dependent antibiotics (<a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0011" title="HanesSD , WoodGC , HerringV , CroceMA , FabianTC , PritchardE , BoucherBA . Intermittent and continuous ceftazidime infusion for critically ill trauma patients. The American Journal of Surgery2000;179(6):436‐40. ">Hanes 2000</a>; <a href="./references#CD008481-bbs2-0018" title="NicolauDP , McNabbJ , LacyMK , QuintilianiR , NightingaleCH . Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. International Journal of Antimicrobial Agents2001;17(6):497‐504. ">Nicolau 2001</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). No statistically significant differences in super‐infections with time–dependent antibiotics were reported (n = 623, RR 0.98, 95% CI 0.53 to 1.83, P = 0.95). No evidence of statistical heterogeneity was found (Chi<sup>2</sup> = 2.81, df = 4, P = 0.59; I<sup>2</sup> = 0%). </p> <p>Two studies reported secondary super‐infections when concentration–dependent antibiotics were compared (<a href="./references#CD008481-bbs2-0008" title="FeldR , ValdiviesoM , BodeyGP , RodriguezV . A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences1977;274(2):179‐88. ">Feld 1977</a>; <a href="./references#CD008481-bbs2-0009" title="FeldR , RachlisA , TuffnellPG , DuncanI , MoranL , PinfoldP , DeBoerG . Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Archives of Internal Medicine1984;144(5):1005‐10. ">Feld 1984</a>). No statistically significant differences in secondary super‐infections were seen with concentration–dependent antibiotics (n = 190, RR 2.20, 95% CI 0.41 to 11.70, P = 0.36). No evidence of statistical heterogeneity was found (Chi<sup>2</sup> = 0.05, df = 1, P = 0.82; I<sup>2</sup> = 0%). </p> <p>When the worst–case scenario was calculated for time‐dependent and concentration‐dependent antibiotics, and when all missing participants were assumed to have secondary super‐infections, no statistically significant differences in infection recurrence were reported (n = 813, RR 1.01, 95% CI 0.73 to 1.40, P = 0.96). </p> <p><b>Serious adverse events</b> (<a href="./references#CD008481-fig-0012" title="">Analysis 1.5</a>) </p> <p>Ten studies reported serious adverse events; all of these studies were conducted to compare time–dependent antibiotics (<a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). No statistically significant differences in participants experiencing at least one serious adverse event were observed (n = 871, RR 1.36, 95% CI 0.80 to 2.30, P = 0.26), and no evidence of statistical heterogeneity was found (Chi<sup>2</sup> = 1.00, df = 1, P = 0.32; I<sup>2</sup> = 0%). </p> <p>When the worst–case scenario was calculated for time‐dependent antibiotics, and when all missing participants were assumed to have had a serious adverse event, no statistically significant differences in serious adverse events were noted (n = 871, RR 1.04, 95% CI 0.67 to 1.62, P = 0.85). </p> <p><b>Withdrawals due to adverse events</b> (<a href="./references#CD008481-fig-0013" title="">Analysis 1.6</a>) </p> <p>Ten studies reported withdrawals due to adverse events; all of these studies compared time–dependent antibiotics (<a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). No statistically significant differences in withdrawals due to adverse events were described (n = 871, RR 2.03, 95% CI 0.52 to 7.95, P = 0.31). Statistical heterogeneity could not be calculated because only one study reported participant withdrawals due to adverse events. </p> <p>When the worst–case scenario was calculated, and when all missing participants were assumed to have withdrawn because of an adverse event, no statistically significant differences in withdrawals due to adverse events were seen (n = 871, RR 0.99, 95% CI 0.66 to 1.50, P = 0.98). </p> <p><b>Adverse events</b> (<a href="./references#CD008481-fig-0014" title="">Analysis 1.7</a>) </p> <p>Five studies reported adverse events; all of these studies were performed to compare time–dependent antibiotics (<a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>). No statistically significant differences in adverse events were observed (n = 575, RR 1.02, 95% CI 0.94 to 1.12, P = 0.63), and no evidence of statistical heterogeneity was found (Chi<sup>2</sup> = 0.37, df = 1, P = 0.54; I<sup>2</sup> = 0%).  </p> <p>When the worst‐case scenario was calculated, in which all missing participants were assumed to have had an adverse event, no statistically significant differences in adverse events were noted (n = 575, RR 1.02, 95% CI 0.94 to 1.12, P = 0.60). </p> <p><b>Subgroup analysis: septic versus non–septic participants</b> </p> <p>Twenty studies included participants with sepsis (met criteria for systemic inflammatory response syndrome with a documented or suspected infection and/or critically unwell admitted to an intensive care unit) (<a href="./references#CD008481-bbs2-0001" title="AdembriC , FallaniS , CassettaMI , ArrigucciS , OttavianoA , PecileP , MazzeiT , DeGaudioR , NovelliA . Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. International Journal of Antimicrobial Agents2008;31(2):122‐9. ">Adembri 2008</a>; <a href="./references#CD008481-bbs2-0002" title="AngusBJ , SmithMD , SuputtamongkolY , MattieH , WalshAL , WuthiekanunV , ChaowagulW , WhiteNJ . Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology2000;49(5):445‐52. ">Angus 2000</a>; <a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0011" title="HanesSD , WoodGC , HerringV , CroceMA , FabianTC , PritchardE , BoucherBA . Intermittent and continuous ceftazidime infusion for critically ill trauma patients. The American Journal of Surgery2000;179(6):436‐40. ">Hanes 2000</a>; <a href="./references#CD008481-bbs2-0014" title="LipmanJ , GomersallCD , GinT , JoyntGM , YoungRJ . Continuous infusion ceftazidime in intensive care: a randomized controlled trial. Journal of Antimicrobial Chemotherapy1999;43(2):309‐11. ">Lipman 1999</a>; <a href="./references#CD008481-bbs2-0016" title="NicolauDP , McNabbJ , LacyMK , LiJ , QuintilianiR , NightingaleCH . Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clinical Drug Investigation1999;18(2):133‐9. ">Nicolau 1999a</a>; <a href="./references#CD008481-bbs2-0017" title="NicolauDP , LacyMK , McNabbJ , QuintilianiR , NightingaleCH . Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infectious Diseases in Clinical Practice1999;8(1):45‐9. ">Nicolau 1999b</a>; <a href="./references#CD008481-bbs2-0018" title="NicolauDP , McNabbJ , LacyMK , QuintilianiR , NightingaleCH . Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. International Journal of Antimicrobial Agents2001;17(6):497‐504. ">Nicolau 2001</a>; <a href="./references#CD008481-bbs2-0020" title="PedeboscqS , DubauB , FrappierS , HernandezV , VeyssieresD , WinnockS , PometanJP . Comparison of 2 administration protocols (continuous or discontinuous) of a time‐dependent antibiotic, Tazocin (French). Pathologie Biologie (Paris)2001;49(7):540‐7. ">Pedeboscq 2001</a>; <a href="./references#CD008481-bbs2-0021" title="RafatiMR , RouiniMR , MojtahedzadehM , NajafiA , TavakoliH , GholamiK , FazeliMR . Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. International Journal of Antimicrobial Agents2006;28(2):122‐7. ">Rafati 2006</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0026" title="SakkaSG , GlaunerAK , BulittaJB , Kinzig‐SchippersM , PfisterW , DrusanoGL , SorgelF . Population pharmacokinetics and pharmacodynamics of continuous versus short‐term infusion of imipenem‐cilastatin in critically ill patients in a randomized, controlled trial. Antimicrobial Agents and Chemotherapy2007;51(9):3304‐10. ">Sakka 2007</a>; <a href="./references#CD008481-bbs2-0028" title="WrightJP , PotgieterPD , ForderAA , BothaP , BrinkworthG , ElishaG , FergusonAD . Gentamicin and penicillin in the treatment of severe respiratory infections. South African Medical Journal1979;55(6):197‐200. ">Wright 1979</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). </p> <p>Fifteen studies reported mortality in septic participants (<a href="./references#CD008481-bbs2-0001" title="AdembriC , FallaniS , CassettaMI , ArrigucciS , OttavianoA , PecileP , MazzeiT , DeGaudioR , NovelliA . Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. International Journal of Antimicrobial Agents2008;31(2):122‐9. ">Adembri 2008</a>; <a href="./references#CD008481-bbs2-0002" title="AngusBJ , SmithMD , SuputtamongkolY , MattieH , WalshAL , WuthiekanunV , ChaowagulW , WhiteNJ . Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology2000;49(5):445‐52. ">Angus 2000</a>; <a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0020" title="PedeboscqS , DubauB , FrappierS , HernandezV , VeyssieresD , WinnockS , PometanJP . Comparison of 2 administration protocols (continuous or discontinuous) of a time‐dependent antibiotic, Tazocin (French). Pathologie Biologie (Paris)2001;49(7):540‐7. ">Pedeboscq 2001</a>; <a href="./references#CD008481-bbs2-0021" title="RafatiMR , RouiniMR , MojtahedzadehM , NajafiA , TavakoliH , GholamiK , FazeliMR . Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. International Journal of Antimicrobial Agents2006;28(2):122‐7. ">Rafati 2006</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0026" title="SakkaSG , GlaunerAK , BulittaJB , Kinzig‐SchippersM , PfisterW , DrusanoGL , SorgelF . Population pharmacokinetics and pharmacodynamics of continuous versus short‐term infusion of imipenem‐cilastatin in critically ill patients in a randomized, controlled trial. Antimicrobial Agents and Chemotherapy2007;51(9):3304‐10. ">Sakka 2007</a>; <a href="./references#CD008481-bbs2-0028" title="WrightJP , PotgieterPD , ForderAA , BothaP , BrinkworthG , ElishaG , FergusonAD . Gentamicin and penicillin in the treatment of severe respiratory infections. South African Medical Journal1979;55(6):197‐200. ">Wright 1979</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). No statistically significant differences in all–cause mortality were reported when time–dependent antibiotics and concentration–dependent antibiotics were analysed together (n = 721, RR 0.82, 95% CI 0.59 to 1.13, P = 0.23). Four studies reported mortality in non–septic participants (<a href="./references#CD008481-bbs2-0008" title="FeldR , ValdiviesoM , BodeyGP , RodriguezV . A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences1977;274(2):179‐88. ">Feld 1977</a>; <a href="./references#CD008481-bbs2-0012" title="LagastH , Meunier‐CarpentierF , KlasterskyJ . Treatment of gram‐negative bacillary septicemia with cefoperazone. European Journal of Clinical Microbiology1983;2(6):554‐8. ">Lagast 1983</a>; <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>). No statistically significant differences in all–cause mortality were noted when time–dependent antibiotics and concentration–dependent antibiotics were analysed together (n = 520, RR 1.32, 95% CI 0.67 to 2.61, P = 0.43). </p> <p>Six studies reported infection recurrence in septic participants; all of these trials were conducted to compare time–dependent antibiotics (<a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). No statistically significant differences in infection recurrence were observed (n = 260, RR 2.90, 95% CI 0.12 to 68.33, P = 0.51). Two studies reported infection recurrence in non–septic participants; all of these trials compared time–dependent antibiotics (<a href="./references#CD008481-bbs2-0012" title="LagastH , Meunier‐CarpentierF , KlasterskyJ . Treatment of gram‐negative bacillary septicemia with cefoperazone. European Journal of Clinical Microbiology1983;2(6):554‐8. ">Lagast 1983</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>). No statistically significant differences in infection recurrence were described (n = 138, RR 1.04, 95% CI 0.27 to 3.99, P = 0.95). </p> <p>Ten studies reported clinical cure in septic participants; all of these studies compared time–dependent antibiotics (<a href="./references#CD008481-bbs2-0001" title="AdembriC , FallaniS , CassettaMI , ArrigucciS , OttavianoA , PecileP , MazzeiT , DeGaudioR , NovelliA . Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. International Journal of Antimicrobial Agents2008;31(2):122‐9. ">Adembri 2008</a>; <a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0018" title="NicolauDP , McNabbJ , LacyMK , QuintilianiR , NightingaleCH . Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. International Journal of Antimicrobial Agents2001;17(6):497‐504. ">Nicolau 2001</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>). No statistically significant differences in clinical cure were reported (n = 465, RR 1.17, 95% CI 0.99 to 1.37, P = 0.06) when a random‐effects model was used. However, a statistically significant difference favouring intermittent antibiotic infusions was seen when a fixed‐effect model was used (n = 465, RR 1.26, 95% CI 1.02 to 1.55, P = 0.03). Five studies reported clinical cure in non–septic participants; all of these trials compared time–dependent antibiotics (<a href="./references#CD008481-bbs2-0004" title="BuckC , BertramN , AckermannT , SauerbruchT , DerendorfH , PaarWD . Pharmacokinetics of piperacillin‐tazobactam: intermittent dosing versus continuous infusion. International Journal of Antimicrobial Agents2005;25(1):62‐7. ">Buck 2005</a>; <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>; <a href="./references#CD008481-bbs2-0015" title="LubaschA , LuckS , HartmutL , MauchH , LorenzJ , BolcskeiP , WelteT . Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. Journal of Antimicrobial Chemotherapy2003;51:659‐64. ">Lubasch 2003</a>; <a href="./references#CD008481-bbs2-0019" title="OkimotoN , IshigaM , NanbaF , KibayashiT , KishimotoM , KuriharaT , HondaY , AsaokaN , TamadaS . Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly (Japanese). Nihon Kokyuki Gakkai Zasshi2009;47(7):553‐7. ">Okimoto 2009</a>; <a href="./references#CD008481-bbs2-0027" title="vanZantenARH , OudijkM , Nohlmans‐PaulssenMKE , van derMeerYG , GirbesARJ , PoldermanKH . Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology2007;63(1):100‐9. ">van Zanten 2007</a>). No statistically significant differences in clinical cure were observed (n = 510, RR 0.96, 95% CI 0.89 to 1.04, P = 0.36). </p> <p>Ten studies reported super‐infection in septic participants; all of these studies compared time‐dependent antibiotics (<a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0010" title="GeorgesB , ConilJM , CougotP , DecunJF , ArchambaudM , SeguinT , ChabanonG , VirenqueC , HouinG , SaivinS . Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics2005;43(8):360‐9. ">Georges 2005</a>; <a href="./references#CD008481-bbs2-0011" title="HanesSD , WoodGC , HerringV , CroceMA , FabianTC , PritchardE , BoucherBA . Intermittent and continuous ceftazidime infusion for critically ill trauma patients. The American Journal of Surgery2000;179(6):436‐40. ">Hanes 2000</a>; <a href="./references#CD008481-bbs2-0018" title="NicolauDP , McNabbJ , LacyMK , QuintilianiR , NightingaleCH . Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. International Journal of Antimicrobial Agents2001;17(6):497‐504. ">Nicolau 2001</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). No statistically significant differences in super‐infection were described (n = 623, RR 0.98, 95% CI 0.53 to 1.83, P = 0.95). Two studies reported super‐infection in non–septic participants; all of these studies compared concentration‐dependent antibiotics (<a href="./references#CD008481-bbs2-0008" title="FeldR , ValdiviesoM , BodeyGP , RodriguezV . A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences1977;274(2):179‐88. ">Feld 1977</a>; <a href="./references#CD008481-bbs2-0009" title="FeldR , RachlisA , TuffnellPG , DuncanI , MoranL , PinfoldP , DeBoerG . Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Archives of Internal Medicine1984;144(5):1005‐10. ">Feld 1984</a>). No statistically significant differences in super‐infection were reported (n = 190, RR 2.20, 95% CI 0.41 to 11.70, P = 0.36). </p> <p>Eight studies addressed serious adverse events and withdrawals due to adverse events in septic participants; all of these compared time‐dependent antibiotics (<a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0006" title="CoussonJ , FlochT , Vernet‐GarnierV , AppriouM , PetitJS , JoveninN , LamiableD , HoizeyG . Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie2005;53:546‐50. ">Cousson 2005</a>; <a href="./references#CD008481-bbs2-0007" title="DeJonghR , HensR , BasmaV , MoutonJW , TulkensPM , CarrynS . Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy2008;61(2):382‐8. ">DeJongh 2008</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0023" title="RobertsJA , KirkpatrickCMJ , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy2009;64(1):142‐50. ">Roberts 2009b</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>; <a href="./references#CD008481-bbs2-0029" title="WysockiM , DelatourF , FaurissonF , RaussA , PeanY , MissetB , ThomasF , TimsitJF , SimilowskiT , MentecH , MierL , DreyfussD , and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy2001;45(9):2460‐7. ">Wysocki 2001</a>). However, no serious adverse events or withdrawals due to adverse events were recorded in these studies; therefore, comparison with non–septic participants could not be performed.  </p> <p>Four studies reported adverse events in septic participants; all of these studies compared time‐dependent antibiotics (<a href="./references#CD008481-bbs2-0005" title="ChytraI , StepanM , BenesJ , PelnarP , ZidkovaA , BergerovaT , PradlR , KasalE . Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial. Critical Care2012;16:R113 (Epub ahead of print). ">Chytra 2012</a>; <a href="./references#CD008481-bbs2-0022" title="RobertsJA , BootsR , RickardCM , ThomasP , QuinnJ , RobertsDM , RichardsB , LipmanJ . Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy2007;59(2):285‐91. ">Roberts 2007</a>; <a href="./references#CD008481-bbs2-0024" title="RobertsJA , RobertsMS , RobertsonTA , DalleyAJ , LipmanJ . Piperacillin penetration into tissue of critically ill patients with sepsis‐bolus versus continuous administration?. Critical Care Medicine2009;37(3):926‐33. ">Roberts 2009c</a>; <a href="./references#CD008481-bbs2-0025" title="RobertsJA , KirkpatrickCMJ , RobertsMS , DalleyAJ , LipmanJ . First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents2010;35:156‐63. ">Roberts 2010</a>). No statistically significant differences in adverse events were observed (n = 313, RR 0.83, 95% CI 0.37 to 1.85, P = 0.66). One study, which compared time‐dependent antibiotics, reported adverse events in non‐septic participants (<a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a>). No statistically significant differences in adverse events were noted (n = 262, RR 1.02, 95% CI 0.94 to 1.12, P = 0.60). </p> <p><b>Sensitivity analysis</b> </p> <p>When studies that did not report allocation concealment procedures were removed from analysis, no statistically significant differences in all–cause mortality were reported (n = 521, RR 1.00, 95% CI 0.63 to 1.58, P = 1.00) nor were differences in infection recurrence described (n = 243, RR 2.90, 95% CI 0.12 to 68.33, P = 0.51). </p> <p>When studies that compared extended interval infusions with intermittent infusions were removed from analysis, no statistically significant differences in all–cause mortality (n = 1187, RR 0.90, 95% CI 0.65 to 1.25, P = 0.53) or infection recurrence were found (n = 398, RR 1.22, 95% CI 0.35 to 4.19, P = 0.76). </p> <p>When studies that stated that open–label antibiotics were permitted were removed from analysis, no statistically significant differences in all–cause mortality (n = 546, RR 1.37, 95% CI 0.71 to 2.67, P = 0.35) or infection recurrence were described (n = 164, RR 1.04, 95% CI 0.27 to 3.99, P = 0.95). </p> <p>The <a href="./references#CD008481-bbs2-0008" title="FeldR , ValdiviesoM , BodeyGP , RodriguezV . A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences1977;274(2):179‐88. ">Feld 1977</a> study included some participants younger than 18 years; therefore, it was removed from analysis. When removed, no statistically significant differences in all‐cause mortality were seen (n = 1121, RR 0.87, 95% CI 0.64 to 1.18, P = 0.37). This study did not contribute data to the infection recurrence outcome. </p> <p>The <a href="./references#CD008481-bbs2-0013" title="LauWK , MercerD , ItaniKM , NicolauDP , KutiJL , MansfieldD , DanaA . Randomized, open‐label, comparative study of piperacillin‐tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra‐abdominal infection. Antimicrobial Agents and Chemotherapy2006;50(11):3556‐61. ">Lau 2006</a> and <a href="./references#CD008481-bbs2-0015" title="LubaschA , LuckS , HartmutL , MauchH , LorenzJ , BolcskeiP , WelteT . Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. Journal of Antimicrobial Chemotherapy2003;51:659‐64. ">Lubasch 2003</a> studies reported clinical success as a composite outcome of clinical cure and clinical improvement, and these studies were removed from the analysis. When they were removed, no statistically significant differences in clinical cure were reported (n = 632, RR 1.06, 95% CI 0.94 to 1.19, P = 0.36). </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008481-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008481-sec-0069"></div> <section id="CD008481-sec-0070"> <h3 class="title" id="CD008481-sec-0070">Summary of main results</h3> <p>No differences in all–cause mortality, infection recurrence, clinical cure, or super‐infection post–therapy were found between continuous antibiotic infusions and intermittent antibiotic infusions. Nor were differences reported when safety outcomes (serious adverse events, withdrawals due to adverse events, and adverse events) were compared. When comparisons between time–dependent and concentration–dependent antibiotics were made, no differences in all–cause mortality or super‐infection post–therapy were noted. </p> <p>Subgroup analyses revealed no differences in all–cause mortality, infection recurrence, or super‐infection post–therapy when septic or critical care participants were compared with non–septic participants. A difference was observed in the subgroup analyses of clinical cure in septic versus non‐septic participants. However, this result was not robust because it was not observed in both random‐effects and fixed‐effect models. Additionally, this result is difficult to interpret because clinical cure was a subjective outcome, and no standard definition was used in the included studies. Clinical cure was defined by clinician judgement as improvement in signs and symptoms of infection, which included assessment of some or all of the following factors: bacteriological eradication, leukocyte counts, vital signs, inflammation, and sputum production. In addition, clinical success was defined as a composite outcome of clinical cure and clinical improvement in two studies. Therefore, it cannot be concluded from these data that greater clinical cure was seen in the intermittent antibiotic infusion group. It is also unclear whether any clinically meaningful differences in clinical cure were noted between continuous antibiotic infusions and intermittent antibiotic infusions because of identified risks of bias due to outcome subjectivity and lack of a robust statistical finding. </p> <p>No differences between continuous and intermittent antibiotic infusions were reported for any sensitivity analyses performed. </p> </section> <section id="CD008481-sec-0071"> <h3 class="title" id="CD008481-sec-0071">Overall completeness and applicability of evidence</h3> <p>A wide range of antibiotics, infections, and organisms were included in this review, and this may allow the results to be broadly generalized. Although continuous infusions are thought to optimise the pharmacokinetic and pharmacodynamic parameters of time–dependent antibiotics, both time–dependent and concentration–dependent antibiotics were included in this analysis, because there is some thought that a lower total daily antibiotic dose could be used during continuous infusions (<a href="./references#CD008481-bbs2-0089" title="NicolauDP , NightingaleCH , BaneviciusMA , FuQ , QuintilianiR . Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent infections. Antimicrobial Agents and Chemotherapy1996;40(1):61‐4. ">Nicolau 1996</a>). This would affect the peak concentration and the area under the curve (estimate of drug exposure) for a drug; therefore, concentration–dependent antibiotics were included to investigate whether any adverse clinical outcomes or effects related to continuous infusions of concentration–dependent antibiotics were noted. Additionally, because the continuous infusion of concentration–dependent antibiotics has not been widely studied, it is not clear whether this dosing strategy would be beneficial or harmful to patients. The results of this study are applicable only to hospitalised patients and may not be applied to outpatient parenteral therapy programs based on the types of patients and settings of trials included in this review.   </p> <p>Several other concerns surround the applicability of these results. One concern is the heterogeneous definition of clinical cure in each study. Measuring an outcome such as clinical cure is especially difficult when clinicians or outcome assessors are not blinded, which was the case in most of the studies included in this review. Also, the use of open–label antibiotics in many of the studies may bias the effect of the intervention to show no difference. However, it would be unethical to limit antibiotic use in patients with severe bacterial infection. Another factor not considered in this review was pathogen susceptibility. It is possible that a difference between interventions was not observed as more highly susceptible pathogens were studied. Outcomes would theoretically be more similar between groups if the pathogens were highly susceptible (i.e. organisms were very sensitive to the effects of study antibiotics) because any suitable antibiotic would be effective no matter the dosing strategy. It could be hypothesized that continuous antibiotic infusions would be of greater benefit in cases of less susceptible organisms. Other confounding factors are the numerous other therapeutic interventions in hospitalised and critically ill patients (such as fluid resuscitation, vasopressor and inotrope use, and blood transfusion) that could also have a substantial impact on mortality, infection recurrence, and clinical cure. This is an important issue despite the fact that only randomised studies were included, because the validity of randomisation is affected by the small size of the included studies. </p> <p>Although all of the trials included were randomised, it is of note that most of the studies had small participant populations. Generally, fewer than 100 participants were included in each study, and in one case, as few as seven participants were included. This is a potential problem because it raises the issue of whether the pooling of small studies for this review has sufficient power to detect a difference between continuous and intermittent antibiotic infusions. It is not clear whether the sample size as a result of pooling would be able to detect differences between the two antibiotic dosing strategies. This becomes an important issue when the safety outcomes of this review are interpreted because only two studies analysed reported participants experiencing an adverse effect or a serious adverse event, and only one study reported participant withdrawal due to an adverse event. This potential under–reporting of safety outcomes makes it difficult to assess the safety of continuous antibiotic infusions and intermittent antibiotic infusions in severe bacterial infection.    </p> <p>Furthermore, for each outcome, the calculated effect estimates in this review are associated with wide confidence intervals and show no particular consistent trend in beneficial or harmful effects with either continuous or intermittent administration. If data were available for outcomes from the trials that did not report on these outcomes, more precise effect estimates could have been calculated and could possibly show advantages or disadvantages for either continuous or intermittent antibiotic administration. It is important to refrain from concluding that outcomes for continuous and intermittent administration are equal, given the quantity of missing information and the possibility that the meta‐analyses are underpowered.    </p> <p>In addition to the limitations already described, many logistical concerns have been raised regarding the administration of continuous infusion antibiotics. Some beta–lactams, such as carbapenems, are thought to be too unstable for continuous infusion (<a href="./references#CD008481-bbs2-0098" title="ViaeneE , ChanteuxH , ServaisH , Mingeot‐LeclercqM , TulkensP . Comparative stability studies of antipseudomonal B‐Lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor‐operated syringes (intensive care units). Antimicrobial Agents and Chemotherapy2002;46(8):2327‐32. ">Viaene 2002</a>). Continuous infusion pumps may increase nursing workload and may limit patient mobility on medical wards, and additional intravenous lines may be required if the antibiotic chosen is not compatible with other medications (<a href="./references#CD008481-bbs2-0069" title="ArianoR , ZelenitskyS , McCormackJ . Should IV antibiotics be administered by prolonged infusion?. Canadian Journal of Hospital Pharmacy2010;63(3):246‐9. ">Ariano 2010</a>). Extending the infusion also occupies an intravenous line that may be essential for other therapies, especially in critically ill patients who have limited intravenous access. As well, it is not known whether continuous infusions would result in increased dosing and administration errors by physicians, pharmacists, and nursing staff. However, several studies have suggested that continuous infusion of antibiotics is more cost–effective compared with intermittent infusions (<a href="./references#CD008481-bbs2-0052" title="McNabbJJ , NightingaleCH , QuintilianiR , NicolauDP . Cost‐effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy2001;21(5):549‐55. ">McNabb 2001</a>; <a href="./references#CD008481-bbs2-0073" title="FloreaNR , KotapatiS , KutiJL , GeisslerEC , NightingaleCH , NicolauDP . Cost analysis of continuous versus intermittent infusion of piperacillin–tazobactam: a time–motion study. American Journal of Health System Pharmacy2003;60(22):2321‐7. ">Florea 2003</a>; <a href="./references#CD008481-bbs2-0079" title="HittCM , NighingaleCH , QuintillianiR , NicolauDP . Cost comparison of single daily IV doses of ceftriaxone versus continuous infusion of cefotaxime. American Journal of Health System Pharmacy1997;54(14):1614‐8. ">Hitt 1997</a>; <a href="./references#CD008481-bbs2-0038" title="GrantE , KutiJ , NicolauD , NightingaleC , QuintilianiR . Clinical efficacy and pharmacoeconomics of a continuous‐infusion piperacillin‐tazobactam program in a large community teaching hospital. Pharmacotherapy2002;22(4):471‐83. ">Grant 2002</a>). Although intermittent antibiotic infusions are the current standard of therapy, some disadvantages merit consideration. Intermittent antibiotic infusions may increase nursing workload for those antibiotics that require multiple daily doses compared with continuous infusion pumps. In the preparation of these multiple antibiotic doses, the chance of dispensing and mixing errors by pharmacy and nursing staff may be increased. Intermittent infusions typically also result in higher peak concentrations of antibiotics, which could lead to an increase in adverse effects related to drug toxicity. Finally, intermittent antibiotic infusions could put the patient at increased infection risk compared with continuous infusions because more frequent access to intravenous lines is required to give multiple daily doses of antibiotics. </p> </section> <section id="CD008481-sec-0072"> <h3 class="title" id="CD008481-sec-0072">Quality of the evidence</h3> <p>The quality of evidence included in this review was very low to moderate according to GRADE considerations (<a href="./references#CD008481-bbs2-0075" title="Version 3.2 for Windows. BrozekJ , OxmanA , SchunemannH . GRADEpro (GRADEprofiler).. The Cochrane Collaboration, 2008. ">GRADEpro 2008</a>; <a href="./references#CD008481-bbs2-0070" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , VistGE , Flack‐YtterY , MeerpohlJ , NorrisS , GuyallGH . GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64:401‐06. ">Balshem 2011</a>; <a href="./references#CD008481-bbs2-0076" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , NorrisS , Falck‐YtterY , GlasziouP , deBeerH , JaeschkeR , RindD , MeerpohlJ , DahmP , SchunemannHJ . GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383‐94. ">Guyatt 2011</a>). Although all 29 studies were randomised, procedures for both generation of the randomisation sequence and allocation concealment were described in only two studies. Only two studies were blinded, and the remaining studies were not blinded, or blinding was not reported and the studies appeared to be unblinded as judged by the authors. Additionally, accounting of missing participants and missing outcomes was not well described in the studies reviewed. It is interesting to note that many included studies were published before the CONSORT guidelines for reporting of RCTs were available. </p> </section> <section id="CD008481-sec-0073"> <h3 class="title" id="CD008481-sec-0073">Potential biases in the review process</h3> <p>This review had a focused objective and used a systematic search strategy to identify studies for potential inclusion. Biases in the review process were minimized by using pre–defined inclusion and exclusion criteria for study selection and standardized data extraction forms to gather data and appraise studies. Although no evidence of statistical heterogeneity was observed for all outcomes studied, several potential sources of heterogeneity (such as variation in outcomes studied, open–label antibiotic use, infection type, and patient co–morbidities) should be considered. Also, the potential for publication bias exists, although the funnel plots for all–cause mortality, infection recurrence, clinical cure, and super‐infection do not seem to indicate this (<a href="#CD008481-fig-0004">Figure 4</a>, <a href="#CD008481-fig-0005">Figure 5</a>, <a href="#CD008481-fig-0006">Figure 6</a>, <a href="#CD008481-fig-0007">Figure 7</a>). Publication bias increases the potential for adverse events, serious adverse events, and withdrawals due to adverse events as a result of the fact that funnel plots could not be analysed because the number of trials reporting these outcomes was insufficient. </p> <div class="figure" id="CD008481-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: continuous vs intermittent antibiotic infusions, outcome. All‐cause mortality." data-id="CD008481-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: continuous vs intermittent antibiotic infusions, outcome. All‐cause mortality. </p> </div> </div> </div> <div class="figure" id="CD008481-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: infection recurrence." data-id="CD008481-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: infection recurrence. </p> </div> </div> </div> <div class="figure" id="CD008481-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: clinical cure." data-id="CD008481-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: clinical cure. </p> </div> </div> </div> <div class="figure" id="CD008481-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: super‐infection." data-id="CD008481-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: super‐infection. </p> </div> </div> </div> </section> <section id="CD008481-sec-0074"> <h3 class="title" id="CD008481-sec-0074">Agreements and disagreements with other studies or reviews</h3> <p>This systematic review is consistent with previously published reviews. A meta–analysis of nine RCTs did not show any statistically significant differences in mortality (OR 0.89, 95% CI 0.48 to 1.64) (<a href="./references#CD008481-bbs2-0081" title="KasiakouSK , SermaidesGJ , MichalopoulosA , SoteriadesES , FalagasME . Continuous versus intermittent intravenous administration of antibiotics: a meta‐analysis of randomised controlled trials. Lancet Infectious Diseases2005;5(9):581‐9. ">Kasiakou 2005b</a>). A potential explanation for the similarity of results is that seven of the nine RCTs in the Kasiakou et al study also met inclusion criteria for this review. The remaining two studies were excluded from this review because one study was a cost‐effectiveness re‐analysis of an already included study, and the other study included nonｰrandomly assigned participants. Moreover, four of the five RCTs that reported mortality data were included in this review. Similar antibiotics, such as beta–lactams, aminoglycosides, and vancomycin, were compared in both reviews. Similar participant populations, such as critical care participants, were compared in both reviews. Although no differences in mortality were reported by Kasiakou et al, these authors still concluded that continuous antibiotic infusions have a clinical advantage compared with intermittent infusions. This conclusion was based on a subgroup analysis in which only trials comparing the same total antibiotic dose showed that clinical failure rates were lower in the continuous infusion group (OR 0.70, 95% CI 0.50 to 0.98) (<a href="./references#CD008481-bbs2-0081" title="KasiakouSK , SermaidesGJ , MichalopoulosA , SoteriadesES , FalagasME . Continuous versus intermittent intravenous administration of antibiotics: a meta‐analysis of randomised controlled trials. Lancet Infectious Diseases2005;5(9):581‐9. ">Kasiakou 2005b</a>). Conversely, a difference favouring intermittent antibiotic infusions for clinical cure in septic participants was observed in this review. However, as has been discussed, the difference observed was not a robust statistical finding. A larger systematic review of 14 RCTs conducted by Roberts et al also did not find any differences in mortality (OR 1.00, 95% CI 0.48 to 2.06) or clinical cure (OR 1.04, 95% CI 0.74 to 1.46) (<a href="./references#CD008481-bbs2-0093" title="RobertsJA , WebbS , PatersonD , HoKM , LipmanJ . A systematic review on clinical benefits of continuous administration of B‐lactam antibiotics. Critical Care Medicine2009;37(6):2071‐8. ">Roberts 2009a</a>). Again, this similarity is likely related to the fact that 13 of the 14 RCTs in the review by Roberts et al are included in this review. The remaining study was not included in this review because it was not randomised. Therefore, both reviews had similar patient populations, study settings, and antibiotics studied. Tamma et al compared only beta–lactam continuous infusions versus intermittent infusions when conducting another systematic review of 14 RCTs. Similar to this review, Tamma et al did not find any differences in mortality (RR 0.92, 95% CI 0.61 to 1.37) or clinical cure (RR 1.00, 95% CI 0.94 to 1.06) (<a href="./references#CD008481-bbs2-0096" title="TammaPD , PutchaN , SuhYD , VanArendonkKJ , RinkeML . Does prolonged B‐lactam infusions improve clinical outcomes compared to intermittent infusions? A meta‐analysis and systematic review of randomized, controlled trials. BMC Infectious Diseases2011;11:181. ">Tamma 2011</a>). Once again, with 12 of the 14 RCTs included in both reviews, this consistency is likely explained. The remaining 2 studies were not included in this review because 1 study was not randomised, and the other study compared different antibiotics, which was an exclusion criterion for this review. </p> <p>Generally, those studies that have shown a trend toward improved outcomes with continuous infusion antibiotics were investigating more resistant organisms in critically ill participants. A cohort study performed by Lodise et al compared 194 participants with a mean APACHE II score of 16, who received piperacillin‐tazobactam extended infusions versus intermittent infusions to treat <i>Pseudomonas aeruginosa</i> (<a href="./references#CD008481-bbs2-0084" title="LodiseTPJr , LomaestroB , DrusanoGL . Piperacillin‐tazobactam for pseudomonas aeruginosa Infection: clinical implications of an extended‐infusion dosing strategy. Clinical Infectious Diseases2007;44(3):357‐63. ">Lodise 2007</a>). Lodise et al found that participants with an APACHE II score &gt; 17 receiving piperacillin‐tazobactam extended infusions had a statistically significant benefit in 14–day mortality (P = 0.04) (<a href="./references#CD008481-bbs2-0084" title="LodiseTPJr , LomaestroB , DrusanoGL . Piperacillin‐tazobactam for pseudomonas aeruginosa Infection: clinical implications of an extended‐infusion dosing strategy. Clinical Infectious Diseases2007;44(3):357‐63. ">Lodise 2007</a>). However, when the overall 14–day mortality was calculated, no statistically significant difference was noted (P = 0.17) (<a href="./references#CD008481-bbs2-0084" title="LodiseTPJr , LomaestroB , DrusanoGL . Piperacillin‐tazobactam for pseudomonas aeruginosa Infection: clinical implications of an extended‐infusion dosing strategy. Clinical Infectious Diseases2007;44(3):357‐63. ">Lodise 2007</a>). Therefore, it could be hypothesized that continuous antibiotic infusions provide clinically meaningful benefit only in the critically ill. However, the subgroup analysis comparing septic or critically ill participants with non–septic participants in this review did not find any differences except for clinical cure in septic participants, which was not robust. A potential explanation for this is that all studies included in this review were RCTs, and the Lodise et al study was a nonｰrandomly assigned retrospective cohort. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008481-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Continuous vs intermittent study flow diagram." data-id="CD008481-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Continuous vs intermittent study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD008481-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD008481-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: continuous vs intermittent antibiotic infusions, outcome. All‐cause mortality." data-id="CD008481-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: continuous vs intermittent antibiotic infusions, outcome. All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: infection recurrence." data-id="CD008481-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: infection recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: clinical cure." data-id="CD008481-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: clinical cure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: super‐infection." data-id="CD008481-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: continuous vs intermittent antibiotic infusions. Outcome: super‐infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous vs intermittent, Outcome 1 All cause mortality." data-id="CD008481-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Continuous vs intermittent, Outcome 1 All cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/references#CD008481-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous vs intermittent, Outcome 2 Infection recurrence." data-id="CD008481-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Continuous vs intermittent, Outcome 2 Infection recurrence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/references#CD008481-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous vs intermittent, Outcome 3 Clinical Cure." data-id="CD008481-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Continuous vs intermittent, Outcome 3 Clinical Cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/references#CD008481-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous vs intermittent, Outcome 4 Superinfection." data-id="CD008481-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Continuous vs intermittent, Outcome 4 Superinfection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/references#CD008481-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous vs intermittent, Outcome 5 Serious Adverse Events." data-id="CD008481-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Continuous vs intermittent, Outcome 5 Serious Adverse Events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/references#CD008481-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous vs intermittent, Outcome 6 Withdrawal due to Adverse Events." data-id="CD008481-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Continuous vs intermittent, Outcome 6 Withdrawal due to Adverse Events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/references#CD008481-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008481-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/urn:x-wiley:14651858:media:CD008481:CD008481-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_t/tCD008481-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous vs intermittent, Outcome 7 Adverse Events." data-id="CD008481-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Continuous vs intermittent, Outcome 7 Adverse Events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/references#CD008481-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/media/CDSR/CD008481/image_n/nCD008481-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008481-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Continuous versus Intermittent Antibiotic Infusions for Treatment of Severe Bacterial Infections</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Continuous versus Intermittent Antibiotic Infusions for Treatment of Severe Bacterial Infections</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patients:</b> Adults with Severe Bacterial Infections<br/> <b>Setting:</b> Hospital<br/> <b>Intervention:</b> Continuous Antibiotic Infusions<br/> <b>Comparison:</b> Intermittent Antibiotic Infusions </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intermittent antibiotic Infusions</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Continuous antibiotic Infusions</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>131 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> <br/> (88 to 157) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/> (0.67 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1241<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infection recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> <br/> (7 to 81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> <br/> (0.35 to 4.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical cure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>584 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>608 per 1000</b> <br/> (555 to 660) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/> (0.95 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>975<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Super‐infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> <br/> (29 to 95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.60 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>813<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b> <br/> (38 to 110) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> <br/> (0.80 to 2.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>871<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> <br/> (4 to 54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.03</b> <br/> (0.52 to 7.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>871<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>441 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>450 per 1000</b> <br/> (415 to 494) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/> (0.94 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>575<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Continuous versus Intermittent Antibiotic Infusions for Treatment of Severe Bacterial Infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/full#CD008481-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008481-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Continuous vs intermittent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.67, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Time‐dependent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.62, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Concentration‐dependent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.50, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Infection recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Time‐dependent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.35, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical Cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Time‐dependent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Superinfection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.60, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Time‐dependent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.53, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Concentration‐dependent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [0.41, 11.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Time‐dependent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.80, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawal due to Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Time‐dependent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [0.52, 7.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Time‐dependent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Continuous vs intermittent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008481.pub2/references#CD008481-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008481.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008481-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008481-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008481-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008481\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008481\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008481\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008481\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008481.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008481.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008481.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008481.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008481.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729233497"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008481.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729233501"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008481.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed7e73b22f55b',t:'MTc0MDcyOTIzMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 